[
  {
    "objectID": "Documentation.html",
    "href": "Documentation.html",
    "title": "Documentation",
    "section": "",
    "text": "Coming soon!"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "The Acute Website",
    "section": "",
    "text": "Principal investigator: Irene Zaghi, M.D.1\nSupervisors: Russell E. Lewis, Pharm.D,2 Monica Cricca, M.D., PhD.,1,3 Vittorio Sambri, M.D., PhD.1,3\n1Laboratorio Unico della AUSL della Romagna, in Pievesestina di Cesena, Italy\n2 Department of Molecular Medicine, University of Padua, Padua, Italy\n3 Department of Diagnostic and Experimental Medicine, University of Bologna, Italy\n\nCollaborators:\n\nJason Roberts, Pharm.D., PhD., NHMRC Leadership Fellow, UQ Centre for Clinical Research, Faculty of Medicine, Acting Director, CCR. Faculty of Medicine\n\nFunding:\n\nDirezione Generale Della Ricerca Dell’ Innovazione in Sanità 2021-Bando Dell Ricerca\nEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2022 Research Grants Program\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAdditional support:\nAnalytical grade antibiotic powder for testing provided by:"
  },
  {
    "objectID": "Workpackage1_singledrug.html",
    "href": "Workpackage1_singledrug.html",
    "title": "Workpackage 1-Single Drug",
    "section": "",
    "text": "In this package we will establish the quantitative relationship of Tpos and KPC-carbapenemase producing Klebsiella pneumoniae inoculum in blood culture bottles. \nThe methods for the assay are a modification of those originally proposed by Kaltsas et al.1 Detailed procedures can be found at this link. Methodology for preparing the test inoculum was adapted from CLSI M21A and M26A guidelines.\n\nBriefly, tubes containing 1.8 mL of pooled healthy human serum are inoculated with 0.2 mL of a series of ten-fold dilutions (5x101 to 5x107 CFU/mL) of the standardised inoculum of each test indicator strains.\nThe sera were are then transferred into BacT⁄ALERT bottles without antibiotic inactivating matrix (Biomérieux Inc) for aerobic incubation for 24 hours and monitored for time to positivity.\nTpos results were used to establish preliminary assay quality control ranges by testing in triplicate for five KPC-carbapenemase producing K. pneumoniae strains (KPC A, B and C strains; NDM, and VIM producing strains) and a reference K. pneumoniae ATCC strain producing ESBL enzyme only. More detailed information on the isolates can be found on the Protocols section.\nWe also compared how Tpos results change if the organism suspension prepared in phosphate buffered saline (PBS-0.9%) versus pooled human serum (serum).\n\n\n\n\nThe relationship between Tpos and the K. pneumoniae inoculum is shown in Figure 1 a linear relationship was observed from approximately 101-108 K. pneumoniae CFU/mL and a Tpos measured from 10.5 hours-4.5 hours over the tested inoculum range, with R2 of 0.92-0.94. The linear relationship of Tpos versus inoculum was consistent if the inoculum was prepared in PBS or pooled human serum as shown in Table 1.\n\n\n\n\n\n\nNote\n\n\n\nIn the paper by Kaltsas et al.1 the reported inoculum was the inoculum introduced in to the bloodculture bottle, 30-40 mL of growth media (depending on the manufacturer).\nTherefore we have followed this precedent of reporting the inoculum introduced into each bottle. Therefore, this does not represent the final test inoculum that need to account for the total 42 mL volume in each bloodculture bottle.\nAll experiments were performed using bloodculture bottles without antibiotic inactivating matrix\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nwp1 <- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1 <-ggplot(wp1, aes(x=inoculum, y=tpos, color=isolates, shape=diluent, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig1 + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\nFigure 1: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nwp1 <- read.csv(\"~/Desktop/ACUTEWEBSITE/wp1a.csv\")\ndf <- data.frame (wp1)\ntable1<-lm_table(df, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%>%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 1:  Effect of inoculum diluent on Tpos \n \n  \n    diluent \n    b0 \n    b1 \n    Rsqr \n    Rsqr_adj \n    Std.Error \n  \n \n\n  \n    pbs \n    32.05074 \n    -2.564975 \n    0.9343070 \n    0.9336227 \n    1.110872 \n  \n  \n    serum \n    33.02361 \n    -2.840223 \n    0.9231703 \n    0.9216023 \n    1.210130 \n  \n\n\n\n\n\n\n\n\n\n\n\n\nCode\n## import raw data from .xlsx file\nlibrary (readxl)\necoliatcc_inoc <- read_excel(\"datasets_single/ecoliatcc_inoculum.xlsx\")\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfigecoli <-ggplot(ecoliatcc_inoc, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig1 + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\nFigure 2: Relationship of time-to-positivity (Tpos) versus test inoculum\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\necoliatcc_inoc <- read_excel(\"datasets_single/ecoliatcc_inoculum.xlsx\")\ndfecoli <- data.frame (ecoliatcc_inoc)\ntable1<-lm_table(dfecoli, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%>%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 2:  Effect of inoculum diluent on Tpos \n \n  \n    diluent \n    b0 \n    b1 \n    Rsqr \n    Rsqr_adj \n    Std.Error \n  \n \n\n  \n    pbs \n    29.52142 \n    -2.295468 \n    0.9933486 \n    0.9929985 \n    0.3948541 \n  \n\n\n\n\n\n\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\nabaumani <- read_excel(\"abaum_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig1 <-ggplot(abaumani, aes(x=inoculum, y=tpos)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig1 + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\nFigure 3: Relationship of time-to-positivity (Tpos) versus test inoculum for Acinetobacter baumanii\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\nabaumani <- read_excel(\"abaum_pbs.xlsx\")\ndf <- data.frame (abaumani)\ntable1<-lm_table(df, log(inoculum) ~ tpos, \"diluent\")\nkbl(table1)%>%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 3:  Effect of inoculum diluent on Tpos for Acinetobacter baumanii \n \n  \n    diluent \n    b0 \n    b1 \n    Rsqr \n    Rsqr_adj \n    Std.Error \n  \n \n\n  \n    pbs \n    28.35235 \n    -2.158901 \n    0.9924317 \n    0.9921406 \n    0.4157561 \n  \n\n\n\n\n\n\n\n\n\n\n\n\nCode\nlibrary (ggplot2)\nlibrary(scales)\ntheme_set(theme_bw())\n## import raw data from .csv file\nlibrary (readxl)\npseudo <- read_excel(\"pseudo_pbs.xlsx\")\n## plot raw data as x-y graph Tpos graph vs. drug concentrations stratified by dilution matrix, method=\"lm\" is the method for linear regression\nfig2f <-ggplot(pseudo, aes(x=inoculum, y=tpos, color=isolates, fill=isolates)) + geom_point(size=4, alpha = 0.5) + \nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,12)) +\ntheme(legend.text=element_text(size=12)) +\ngeom_smooth(aes(linetype=diluent), method=lm , color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE )\nfig2f + theme_bw(base_size = 14)+ scale_x_log10(name=\"Inoculum CFU/mL\", breaks = trans_breaks(\"log10\",n=7, function(x) 10^x),labels = trans_format(\"log10\", math_format(10^.x)))\n\n\n\n\n\nFigure 4: Relationship of time-to-positivity (Tpos) versus test inoculum for Pseudomonas aeruginosa\n\n\n\n\n\n\nCode\nlibrary(forestmangr)\nlibrary(kableExtra)\nlibrary (readxl)\npseudo <- read_excel(\"pseudo_pbs.xlsx\")\ndf_pseudo <- data.frame (pseudo)\ntable2<-lm_table(df_pseudo, log(inoculum) ~ tpos, \"diluent\")\nkbl(table2)%>%\nkable_paper(\"hover\", full_width = F, position=\"left\")\n\n\n\n\nTable 4:  Effect of inoculum diluent on Tpos for pseudomonas aeruginosa \n \n  \n    diluent \n    b0 \n    b1 \n    Rsqr \n    Rsqr_adj \n    Std.Error \n  \n \n\n  \n    pbs \n    26.16852 \n    -1.465734 \n    0.9842056 \n    0.9838108 \n    0.59305 \n  \n\n\n\n\n\n\n\n\n\n\nThese data confirm that Tpos exhibits a wide dynamic range and reproducible relationship as a surrogate indicator for viable CFU/mL."
  },
  {
    "objectID": "Workpackage1_singledrug.html#workpackage-1b-effect-of-antibiotic-exposure-on-tpos",
    "href": "Workpackage1_singledrug.html#workpackage-1b-effect-of-antibiotic-exposure-on-tpos",
    "title": "Workpackage 1-Single Drug",
    "section": "WORKPACKAGE 1B: EFFECT OF ANTIBIOTIC EXPOSURE ON TPOS",
    "text": "WORKPACKAGE 1B: EFFECT OF ANTIBIOTIC EXPOSURE ON TPOS\n\nMETHODS\nThis workpackage explores how cantibiotic concentrations alters Tpos for a standard (1x104 CFU/mL) inoculum of Enterobacterales.\n\n\nRESULTS\n\n\n\nCEFTAZIDIME-AVIBACTAM\n\nPreliminary experiments KPC and NDM isolates\nAs shown in Figure 5, a marked increased in the Tpos for KPC_B from < 10 hrs to > 24 hrs when CAZ/AVI concentrations surpassed 1 mg/L. In contrast, the negative control KPC_NDM strain exhibited consistent Tpos < 10hr at all test concentrations with lack of antimicrobial activity. Trends in Tpos relative to antibiotic exposure were fitted by Loess.\n\n\nCode\nlibrary (ggplot2)\ntheme_set(theme_bw())\nceftaz <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_single/ceftazidime.csv\")\nggplot(ceftaz, aes(x=conc_s, y=tpos, color=isolate, shape=isolate)) + \n  geom_point(size=4, alpha = 0.7) + \n  geom_smooth(aes(linetype=isolate), method= loess, color=\"black\", fill=\"#69b3a2\", se=TRUE, inherit.aes = TRUE ) +\nscale_x_log10(name=\"CAZ/AVI conc, mg/L\") +\nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,25)) \n\n\n\n\n\nFigure 5: Effect of ceftazidime/aviactam concentrations on Tpos of K. pneumoniae\n\n\n\n\n\n\nTable 5: Isolates used for testing\n\n\n\n\n\n\n\nIsolate\nCarbapenemase enzyme\nCeftazidime/avibactam Etest MIC (mg/L)\n\n\n\n\nKlebsiella pneumoniae KPC- B\nKPC-3\n1\n\n\nKlebsiella pneumoniae NDM\nNDM-2\n>64\n\n\n\n\n\n\n\n\nK. pneumoniae ATCC 700603 (MIC 0.75 mg/L) powder 4:1\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7a <- read_excel(\"datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\nfit_atcc <- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit_atcc, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 6: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7a <- read_excel(\"datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\nfit_atcc <- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit_atcc, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 6:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    23.87874 \n    19.31716 \n    28.44033 \n  \n  \n    0.25 \n    26.93812 \n    24.06902 \n    29.80723 \n  \n  \n    0.5 \n    30.38948 \n    29.11007 \n    31.66888 \n  \n  \n    0.75 \n    34.28302 \n    31.38838 \n    37.17767 \n  \n  \n    0.9 \n    38.67541 \n    33.84814 \n    43.50268 \n  \n  \n    0.95 \n    41.98020 \n    33.98412 \n    49.97627 \n  \n\n\n\n\n\n\n\n\n\n\nK. pneumoniae ATCC 700603 (MIC 0.75 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7b <- read_excel(\"datasets_single/kpatcc_caz_avi_powderfix4.xlsx\")\nfit_atcc2 <- drda(tpos ~ ctz_s, data=caz_avi_7b, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit_atcc2, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 7: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7a <- read_excel(\"datasets_single/kpatcc_caz_avi_powderfix4.xlsx\")\nfit7a <- drda(tpos ~ ctz_s, data=caz_avi_7a, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit7a, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 7:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    8.099087 \n    7.038485 \n    9.159689 \n  \n  \n    0.25 \n    9.235833 \n    8.728989 \n    9.742676 \n  \n  \n    0.5 \n    10.532127 \n    10.149119 \n    10.915134 \n  \n  \n    0.75 \n    12.010361 \n    10.856802 \n    13.163921 \n  \n  \n    0.9 \n    13.696074 \n    11.685276 \n    15.706872 \n  \n  \n    0.95 \n    14.975851 \n    12.415855 \n    17.535846 \n  \n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) commercial\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_4 <- read_excel(\"datasets_single/kpcb_caz_avi_com.xlsx\")\nfit4 <- drda(tpos ~ ctz_s, data=caz_avi_4, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit4, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 8: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_4 <- read_excel(\"datasets_single/kpcb_caz_avi_com.xlsx\")\nfit4 <- drda(tpos ~ ctz_s, data=caz_avi_4, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit4, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 8:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    73.66731 \n    71.92413 \n    75.41048 \n  \n  \n    0.25 \n    78.61720 \n    77.51043 \n    79.72397 \n  \n  \n    0.5 \n    83.89969 \n    83.05534 \n    84.74404 \n  \n  \n    0.75 \n    89.53712 \n    88.10788 \n    90.96636 \n  \n  \n    0.9 \n    95.55335 \n    93.12523 \n    97.98147 \n  \n  \n    0.95 \n    99.87460 \n    96.42020 \n    103.32901 \n  \n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) powder 4:1\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_6 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nfit6 <- drda(tpos ~ ctz_s, data=caz_avi_6, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit6, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 9: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_6 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nfit6 <- drda(tpos ~ ctz_s, data=caz_avi_6, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit6, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 9:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    68.88793 \n    61.14631 \n    76.62954 \n  \n  \n    0.25 \n    75.52374 \n    71.50425 \n    79.54322 \n  \n  \n    0.5 \n    82.79876 \n    79.85671 \n    85.74080 \n  \n  \n    0.75 \n    90.77456 \n    83.70890 \n    97.84023 \n  \n  \n    0.9 \n    99.51866 \n    86.97415 \n    112.06317 \n  \n  \n    0.95 \n    105.94237 \n    88.43755 \n    123.44720 \n  \n\n\n\n\n\n\n\n\n\n\nKPC A (MIC 2 mg/L) commerical\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concencentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_7 <- read_excel(\"datasets_single/kpca_caz_avi_com.xlsx\")\nfit7 <- drda(tpos ~ ctz_s, data=caz_avi_7, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit7, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 10: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parametersestiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_7 <- read_excel(\"datasets_single/kpca_caz_avi_com.xlsx\")\nfit7 <- drda(tpos ~ ctz_s, data=caz_avi_7, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit7, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 10:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    143.5857 \n    138.9952 \n    148.1763 \n  \n  \n    0.25 \n    154.0912 \n    151.7888 \n    156.3936 \n  \n  \n    0.5 \n    165.3653 \n    163.4974 \n    167.2333 \n  \n  \n    0.75 \n    177.4643 \n    172.9862 \n    181.9424 \n  \n  \n    0.9 \n    190.4485 \n    183.1369 \n    197.7601 \n  \n  \n    0.95 \n    199.8183 \n    190.5343 \n    209.1023 \n  \n\n\n\n\n\n\n\n\n\n\nKPC A (MIC 2 mg/L) powder 4:1\n\n\nCode\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_8 <- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nfit8 <- drda(tpos ~ ctz_s, data=caz_avi_8, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit8, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 11: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parametersestiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_8 <- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nfit8 <- drda(tpos ~ ctz_s, data=caz_avi_8, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit8, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 11:  Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    125.7716 \n    114.3869 \n    137.1562 \n  \n  \n    0.25 \n    143.8460 \n    136.1835 \n    151.5085 \n  \n  \n    0.5 \n    164.5179 \n    158.8981 \n    170.1377 \n  \n  \n    0.75 \n    188.1605 \n    179.1859 \n    197.1350 \n  \n  \n    0.9 \n    215.2007 \n    197.7571 \n    232.6444 \n  \n  \n    0.95 \n    235.7798 \n    202.9734 \n    268.5861 \n  \n\n\n\n\n\n\n\n\n\n\nKPC A (MIC 2 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_9 <- read_excel(\"datasets_single/kpca_caz_avi_powder_fix4.xlsx\")\nfit9 <- drda(tpos ~ ctz_s, data=caz_avi_9, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit9, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 12: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estiamtes plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_9 <- read_excel(\"datasets_single/kpca_caz_avi_powder_fix4.xlsx\")\nfit9 <- drda(tpos ~ ctz_s, data=caz_avi_9, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit9, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 12:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    26.02302 \n    22.05197 \n    29.99406 \n  \n  \n    0.25 \n    37.21041 \n    34.05205 \n    40.36876 \n  \n  \n    0.5 \n    53.20729 \n    50.04995 \n    56.36463 \n  \n  \n    0.75 \n    76.08130 \n    70.56354 \n    81.59905 \n  \n  \n    0.9 \n    108.78892 \n    81.37114 \n    136.20669 \n  \n  \n    0.95 \n    138.74444 \n    47.74622 \n    229.74266 \n  \n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_10 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_fix4.xlsx\")\nfit10<- drda(tpos ~ ctz_s, data=caz_avi_10, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit10, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 13: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameters estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_10 <- read_excel(\"datasets_single/kpcb_caz_avi_powder_fix4.xlsx\")\nfit10 <- drda(tpos ~ ctz_s, data=caz_avi_10, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit10, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 13:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    21.16519 \n    15.15120 \n    27.17918 \n  \n  \n    0.25 \n    27.06283 \n    22.30567 \n    31.81998 \n  \n  \n    0.5 \n    34.60383 \n    31.40317 \n    37.80449 \n  \n  \n    0.75 \n    44.24612 \n    39.07653 \n    49.41571 \n  \n  \n    0.9 \n    56.57521 \n    43.63228 \n    69.51813 \n  \n  \n    0.95 \n    66.87013 \n    38.60827 \n    95.13199 \n  \n\n\n\n\n\n\n\n\n\n\nKPC B (MIC 1 mg/L) high inoculum\nWe examined how the relationship of Tpos vs. ceftazidime/avibactam concentrations changes when tested against a higher inoculum (1x107 CFU/mL). The same methodology as described above was used for testing. As shown in Figure 14 and Table 14 the EC50 and EC90 were marginally higher when tested at the higher inoculum with a more shallow dose-response relationship.\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_5 <- read_excel(\"datasets_single/kpcb_caz_avi_com_hinoc.xlsx\")\nfithinc <- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fithinc, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 14: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a high-inoculum\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 <- read_excel(\"datasets_single/kpcb_caz_avi_com_hinoc.xlsx\")\nfithinc <- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fithinc, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 14:  Pharmacodynamic estimates for a high-inoculum \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    82.08148 \n    71.35951 \n    92.80344 \n  \n  \n    0.25 \n    117.28496 \n    109.48524 \n    125.08468 \n  \n  \n    0.5 \n    167.58667 \n    159.06133 \n    176.11201 \n  \n  \n    0.75 \n    239.46201 \n    222.24533 \n    256.67869 \n  \n  \n    0.9 \n    342.16357 \n    290.42168 \n    393.90546 \n  \n  \n    0.95 \n    436.16833 \n    240.82684 \n    631.50983 \n  \n\n\n\n\n\n\n\n\n\n\nKPC Catania (MIC 16 mg/L) powder 4:1\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_catan <- read_excel(\"datasets_single/kpccatania_caz_avi_powder_4-1.xlsx\")\nfitcat <- drda(tpos ~ ctz_s, data=caz_avi_catan, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcat, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 15: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a resistant strain\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 <- read_excel(\"datasets_single/kpccatania_caz_avi_powder_4-1.xlsx\")\nfitcat <- drda(tpos ~ ctz_s, data=caz_avi_catan, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitcat, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 15:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    357.0678 \n    344.5988 \n    369.5368 \n  \n  \n    0.25 \n    399.4416 \n    391.4077 \n    407.4755 \n  \n  \n    0.5 \n    446.8440 \n    438.8360 \n    454.8519 \n  \n  \n    0.75 \n    499.8716 \n    486.9293 \n    512.8140 \n  \n  \n    0.9 \n    559.1922 \n    538.6586 \n    579.7258 \n  \n  \n    0.95 \n    603.5119 \n    566.2421 \n    640.7818 \n  \n\n\n\n\n\n\n\n\n\n\nKPC Catania (MIC 16 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_5 <- read_excel(\"datasets_single/kpccatania_caz_avi_powderfix.xlsx\")\nfitcat5 <- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcat5, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 16: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a high-inoculum\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 <- read_excel(\"datasets_single/kpccatania_caz_avi_powderfix.xlsx\")\nfit5 <- drda(tpos ~ ctz_s, data=caz_avi_5, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit5, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 16:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    227.1879 \n    181.0095 \n    273.3664 \n  \n  \n    0.25 \n    292.7908 \n    255.0843 \n    330.4973 \n  \n  \n    0.5 \n    377.3372 \n    356.2659 \n    398.4084 \n  \n  \n    0.75 \n    486.2972 \n    454.9664 \n    517.6279 \n  \n  \n    0.9 \n    626.7205 \n    552.7132 \n    700.7278 \n  \n  \n    0.95 \n    744.7437 \n    610.2525 \n    879.2349 \n  \n\n\n\n\n\n\n\n\n\n\nKPC K. pneumoniae KPRAD (MIC 0.5 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_kprad <- read_excel(\"datasets_single/kp_PRAD_caz_avi_powder4-1.xlsx\")\nfitkprad <- drda(tpos ~ ctz_s, data=caz_avi_kprad, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitkprad, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 17: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against KPC- producing K. pneumoniae\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_kprad <- read_excel(\"datasets_single/kp_PRAD_caz_avi_powder4-1.xlsx\")\nfitkprad <- drda(tpos ~ ctz_s, data=caz_avi_kprad, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitkprad, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 17:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    45.60828 \n    44.00945 \n    47.20710 \n  \n  \n    0.25 \n    48.96778 \n    47.95219 \n    49.98337 \n  \n  \n    0.5 \n    52.57475 \n    51.68561 \n    53.46388 \n  \n  \n    0.75 \n    56.44741 \n    54.94883 \n    57.94598 \n  \n  \n    0.9 \n    60.60532 \n    58.19775 \n    63.01290 \n  \n  \n    0.95 \n    63.60696 \n    59.97950 \n    67.23441 \n  \n\n\n\n\n\n\n\n\nK. pneumoniae KFAB ESBL (MIC 0.38 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_kfab <- read_excel(\"datasets_single/kp_FAB_caz_avi_powder4-1.xlsx\")\nfitkfab <- drda(tpos ~ ctz_s, data=caz_avi_kfab, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitkfab, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 18: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against KPC- producing K. pneumoniae\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_kfab <- read_excel(\"datasets_single/kp_FAB_caz_avi_powder4-1.xlsx\")\nfitkfab <- drda(tpos ~ ctz_s, data=caz_avi_kfab, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitkprad, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 18:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    45.60828 \n    44.00945 \n    47.20710 \n  \n  \n    0.25 \n    48.96778 \n    47.95219 \n    49.98337 \n  \n  \n    0.5 \n    52.57475 \n    51.68561 \n    53.46388 \n  \n  \n    0.75 \n    56.44741 \n    54.94883 \n    57.94598 \n  \n  \n    0.9 \n    60.60532 \n    58.19775 \n    63.01290 \n  \n  \n    0.95 \n    63.60696 \n    59.97950 \n    67.23441 \n  \n\n\n\n\n\n\n\n\nK. pneumoniae WT (MIC 0.125 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_wt2 <- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt <- drda(tpos ~ ctz_s, data=caz_avi_wt2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitwt, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 19: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a wt strain\n\n\n\n\n\n\nCode\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_wt2 <- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt <- drda(tpos ~ ctz_s, data=caz_avi_wt2, mean_function = \"loglogistic4\", max_iter = 1000)\n\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 <- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt2 <- drda(tpos ~ ctz_s, data=caz_avi_wt2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitwt, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 19:  Pharmacodynamic estimates K. pneumoniae WT (MIC 0.125 mg/L) \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    4.104039 \n    3.907545 \n    4.300533 \n  \n  \n    0.25 \n    4.853535 \n    4.727647 \n    4.979422 \n  \n  \n    0.5 \n    5.739906 \n    5.602824 \n    5.876987 \n  \n  \n    0.75 \n    6.788149 \n    6.522560 \n    7.053738 \n  \n  \n    0.9 \n    8.027827 \n    7.540413 \n    8.515241 \n  \n  \n    0.95 \n    8.997963 \n    8.099929 \n    9.895996 \n  \n\n\n\n\n\n\n\n\n\n\nK. pneumoniae WT (MIC 0.125 mg/L) fixed 4 mg/L\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_wt <- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt <- drda(tpos ~ ctz_s, data=caz_avi_wt, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitwt, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 20: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against a wt strain\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_5 <- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\nfitwt <- drda(tpos ~ ctz_s, data=caz_avi_wt, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitwt, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 20:  Pharmacodynamic estimates K. pneumoniae WT (MIC 0.125 mg/L) \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    4.104039 \n    3.907545 \n    4.300533 \n  \n  \n    0.25 \n    4.853535 \n    4.727647 \n    4.979422 \n  \n  \n    0.5 \n    5.739906 \n    5.602824 \n    5.876987 \n  \n  \n    0.75 \n    6.788149 \n    6.522560 \n    7.053738 \n  \n  \n    0.9 \n    8.027827 \n    7.540413 \n    8.515241 \n  \n  \n    0.95 \n    8.997963 \n    8.099929 \n    9.895996 \n  \n\n\n\n\n\n\n\n\n\n\nE. coli ATCC 25922 (MIC 0.19 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncaz_avi_ecoli <- read_excel(\"datasets_single/ecoliatcc_caz_avi_powder4-1.xlsx\")\nfitecoli <- drda(tpos ~ ctz_s, data=caz_avi_ecoli, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitecoli, xlab = \"CAZ/AVI serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 21: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations against E. coli ATCC 25922 (MIC 0.19 mg/L)\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncaz_avi_ecoli <- read_excel(\"datasets_single/ecoliatcc_caz_avi_powder4-1.xlsx\")\nfitecoli <- drda(tpos ~ ctz_s, data=caz_avi_ecoli, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitecoli, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 21:  Pharmacodynamic estimates for a high-inoculum \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    3.823371 \n    3.241785 \n    4.404957 \n  \n  \n    0.25 \n    4.312649 \n    3.937461 \n    4.687837 \n  \n  \n    0.5 \n    4.864540 \n    4.644781 \n    5.084298 \n  \n  \n    0.75 \n    5.487056 \n    5.137118 \n    5.836995 \n  \n  \n    0.9 \n    6.189236 \n    5.480141 \n    6.898332 \n  \n  \n    0.95 \n    6.717490 \n    5.482243 \n    7.952737 \n  \n\n\n\n\n\n\n\n\nCOMPARISON OF POSSIBLE INDICATOR ISOLATES\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nkpca <- read_excel(\"datasets_single/kpca_caz_avi_powder_4-1.xlsx\")\nkpcb <- read_excel(\"datasets_single/kpcb_caz_avi_powder_4-1.xlsx\")\nkpccatania <- read_excel(\"datasets_single/kpccatania_caz_avi_powder_4-1.xlsx\")\ncaz_avi_kfab <- read_excel(\"datasets_single/kp_FAB_caz_avi_powder4-1.xlsx\")\nkpwt <- read_excel(\"datasets_single/kpwt_caz_avi_powder_4-1.xlsx\")\ncaz_avi_kprad <- read_excel(\"datasets_single/kp_PRAD_caz_avi_powder4-1.xlsx\")\nkpatcc <- read_excel(\"datasets_single/kpatcc_caz_avi_powder4-1.xlsx\")\n\n## fit models for each of the isolates\nfitkpca <- drda(tpos ~ ctz_s, kpca, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpcatcc <- drda(tpos ~ ctz_s, kpatcc, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpcb <- drda(tpos ~ ctz_s, kpcb, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpccatania <- drda(tpos ~ ctz_s, kpccatania, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkpwt <- drda(tpos ~ ctz_s, kpwt, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkfab <- drda(tpos ~ ctz_s, data=caz_avi_kfab, mean_function = \"loglogistic4\", max_iter = 1000)\nfitkprad <- drda(tpos ~ ctz_s, data=caz_avi_kprad, mean_function = \"loglogistic4\", max_iter = 1000)\n## plot all of the isolates together\np <-plot(fitkpwt, fitkprad, fitkfab, fitkpcatcc, fitkpcb, fitkpca, fitkpccatania, base=\"10\", xlab = \"Ceftazidime-avibactam conc. (mg/L)\", ylab = \"Tpos\",cex = 0.9, legend_location=\"topleft\", legend = c(\"0.125 mg/L\", \"0.38 mg/L\",  \"0.5 mg/L\", \"0.75 mg/L\", \"1 mg/L\", \"2 mg/L\", \"16 mg/L\")) \n\n\n\n\n\nFigure 22: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCONCLUSIONS\nThese data demonstrate that Tpos is a robust PD endpoint and the relationship of ceftazidime/avibactam concentrations versus Tpos follows classical sigmoidal dose response relationship with a steep transitional portion of the dose response curve that occurs near the MIC of the pathogen. Although ED50/90 estimates were broadly similar if the commercial (pharmaceutical) and analytical powder formulations were tested, used of high-fixed concentrations of avibactam or testing at very high K. pneumoniae inocula resulted in broader concentration-effect curves and higher EC50/90 estimates.  \n\n\n\n\nMEROPENEM\n\nK. pneumoniae ATCC (MIC 0.03 mg/L)\n\nThe impact of increasing meropenem concentrations on Tpos observed with the ATCC ESBL producing Klebsiella pneumoniae was tested using similar methodology as previously described\nAnalytical powder was used to produce serum concentration\nAs shown in Figure 23, Tpos increased as meropenem concentrations surpassed the MIC, with an estimated pharmacodynamic parameters consistent with previous experiments that showed transition in the EC50/EC90 at simulated serum concentrations near the MIC as shown in Table 22.\n\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero <- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit11, xlab = \"Meropenem serum conc. (mg/L)\", ylab = \"Tpos (hr)\", xlim =c(0,100))\n\n\n\n\n\nFigure 23: Pharmacodynamic relationship of Tpos to meropenem concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nmero <- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit11, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 22:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    1.165027 \n    1.026833 \n    1.303220 \n  \n  \n    0.25 \n    1.460430 \n    1.351831 \n    1.569029 \n  \n  \n    0.5 \n    1.830736 \n    1.764894 \n    1.896577 \n  \n  \n    0.75 \n    2.294935 \n    2.177266 \n    2.412605 \n  \n  \n    0.9 \n    2.876837 \n    2.586027 \n    3.167648 \n  \n  \n    0.95 \n    3.354810 \n    2.861582 \n    3.848038 \n  \n\n\n\n\n\n\n\n\nKPC B (MIC 32 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero2 <- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit11, xlab = \"Meropenem serum conc. (mg/L)\", ylab = \"Tpos (hr)\", xlim =c(0,100))\n\n\n\n\n\nFigure 24: Pharmacodynamic relationship of Tpos to meropenem concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nmero2 <- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nfit11 <- drda(tpos ~ mero_s, data=mero2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit11, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 23:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    39.27741 \n    38.19835 \n    40.35648 \n  \n  \n    0.25 \n    40.68575 \n    39.82820 \n    41.54329 \n  \n  \n    0.5 \n    42.14458 \n    41.17684 \n    43.11232 \n  \n  \n    0.75 \n    43.65572 \n    42.30388 \n    45.00756 \n  \n  \n    0.9 \n    45.22105 \n    43.33285 \n    47.10925 \n  \n  \n    0.95 \n    46.31764 \n    43.91272 \n    48.72257 \n  \n\n\n\n\n\n\n\n\nComparison of ATCC and KPC B isolates\n A comparison of meropenem activity against the ATCC ESBL-producing reference (MIC 0.03 mg/L) and KPC-carbapenemase producing K. pneumoniae isolates are shown in Figure 25. The meropenem EC50 measured by Tpos was 23-fold higher for the KPC-carbapenemase producing isolate versus the the ESBL-producing ATCC isolate. Despite variability in the response was noted for the KPC-B isolate at 20 mg/L and 80 mg/mL concentrations (experiments are currently being repeated), the EC50 were nearly identical (indicated by the dotted lines) when corrected for pathogen MIC. These data suggest that it may be possible to substitute sensitive indicator isolates with low MICs to predict pharmacodynamic responses of isolates with higher MICs.\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nmero2 <- read_excel(\"datasets_single/KPCB_meropenem.xlsx\")\nmero <- read_excel(\"datasets_single/ATCC_meropenem.xlsx\")\nfit4a <- drda(tpos ~ mero, mero, mean_function = \"loglogistic4\", max_iter = 1000)\nfit4b <- drda(tpos ~ mero, mero2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit4a, fit4b, xlab = \"Meropenem conc. (mg/L)\", ylab = \"Tpos\",cex = 0.9,legend = c(\"KP ATCC ESBL\", \"KP KPC_2\"))\n\n\n\n\n\nFigure 25: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCONCLUSIONS\nSimilar to cefetazidime-avibactam, experiments with meropenem demonstrated that Tpos is a robust PD endpoint and the relationship of meropenem concentrations versus Tpos follows classical sigmoidal dose response relationship with a steep transitional portion of the dose response curve that occurs near the MIC of the pathogen. \nA key observation is that the pharmacodynamics were similar when meropenem was tested against a highly-susceptible ATCC isolate (MIC 0.03 mg/L) and and the KPC-producing K.pneumoniae B isolate (MIC 32 mg/L) with at proportional difference in the EC50/90. Therefore, it may be possible to use highly-susceptible “indicator” strains for testing to predict activity against more resistant isolates. This is important because direct testing of 1 mL inoculum may routinely result in limited antimicrobial activity measured by Tpos (<10 hours) as dilutional effects when the serum samples is introduced into the bottle containing a total volume of 42 mL will reduce the actual testing concentrations of the antibiotics below the MIC for highly resistant pathogens.   This effect could be counteracted by testing with highly sensitive “indicator” isolates based on the expected serum concentrations of the antibiotic.\n\n\n\n\nGENTAMICIN\n\nKPC A (MIC 2 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to gentamicin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ngent1 <- read_excel(\"datasets_single/KPCA_gent.xlsx\")\nfit12 <- drda(tpos ~ gent_s, data=gent1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit12, xlab = \"Gentamicin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 26: Pharmacodynamic relationship of Tpos to gentamicin concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ngent1 <- read_excel(\"datasets_single/KPCA_gent.xlsx\")\nfit12 <- drda(tpos ~ gent_s, data=gent1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit12, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 24:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    56.65250 \n    53.43037 \n    59.87462 \n  \n  \n    0.25 \n    62.53591 \n    60.25523 \n    64.81660 \n  \n  \n    0.5 \n    69.03033 \n    67.01957 \n    71.04109 \n  \n  \n    0.75 \n    76.19920 \n    73.71019 \n    78.68821 \n  \n  \n    0.9 \n    84.11256 \n    79.42354 \n    88.80158 \n  \n  \n    0.95 \n    89.95932 \n    78.37830 \n    101.54033 \n  \n\n\n\n\n\n\n\n\nKPC B (MIC 0.5 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to gentamicin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ngent2 <- read_excel(\"datasets_single/KPCB_gent.xlsx\")\nfit13 <- drda(tpos ~ gent_s, data=gent2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit13, xlab = \"Gentamicin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 27: Pharmacodynamic relationship of Tpos to gentamicin concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ngent2 <- read_excel(\"datasets_single/KPCB_gent.xlsx\")\nfit13 <- drda(tpos ~ gent_s, data=gent2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit13, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 25:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    18.56332 \n    16.93133 \n    20.19530 \n  \n  \n    0.25 \n    19.92766 \n    19.06150 \n    20.79382 \n  \n  \n    0.5 \n    21.39227 \n    20.34817 \n    22.43636 \n  \n  \n    0.75 \n    22.96452 \n    20.81244 \n    25.11660 \n  \n  \n    0.9 \n    24.65233 \n    21.10862 \n    28.19605 \n  \n  \n    0.95 \n    25.87062 \n    20.96263 \n    30.77861 \n  \n\n\n\n\n\n\n\n\nCONCLUSIONS\n\n\n\n\nCOLISTIN\n\nKPC B (MIC 0.125 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to colistin concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncoli1 <- read_excel(\"datasets_single/KPCB_coli.xlsx\")\nfit14 <- drda(tpos ~ coli_s, data=coli1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit14, xlab = \"Colistin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 28: Pharmacodynamic relationship of Tpos to colistin concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncoli1 <- read_excel(\"datasets_single/KPCB_coli.xlsx\")\nfit14 <- drda(tpos ~ coli_s, data=coli1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit14, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 26:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    3.814341 \n    3.374386 \n    4.254296 \n  \n  \n    0.25 \n    4.696574 \n    4.395993 \n    4.997155 \n  \n  \n    0.5 \n    5.782863 \n    5.463324 \n    6.102402 \n  \n  \n    0.75 \n    7.120404 \n    6.500514 \n    7.740293 \n  \n  \n    0.9 \n    8.767309 \n    7.696486 \n    9.838132 \n  \n  \n    0.95 \n    10.100091 \n    8.130500 \n    12.069682 \n  \n\n\n\n\n\n\n\n\nCONCLUSIONS\n\n\n\n\nMEROPENEM-VABORBACTAM\n\nKPC B (MIC X mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to meropenem-vaborbactam concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nvabo1 <- read_excel(\"datasets_single/KPCB_vabo.xlsx\")\nfit14 <- drda(tpos ~ vabo_s, data=vabo1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit14, xlab = \"Meropenem-vabobactam serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 29: Pharmacodynamic relationship of Tpos to meropenem-vaborbactam concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nvabo1 <- read_excel(\"datasets_single/KPCB_vabo.xlsx\")\nfit14 <- drda(tpos ~ vabo_s, data=vabo1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit14, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 27:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    5.391292 \n    4.092373 \n    6.690211 \n  \n  \n    0.25 \n    7.797856 \n    6.671079 \n    8.924633 \n  \n  \n    0.5 \n    11.278661 \n    10.098053 \n    12.459269 \n  \n  \n    0.75 \n    16.313228 \n    13.817427 \n    18.809029 \n  \n  \n    0.9 \n    23.595123 \n    18.006802 \n    29.183445 \n  \n  \n    0.95 \n    30.327549 \n    19.089870 \n    41.565227 \n  \n\n\n\n\n\n\n\n\nCONCLUSIONS\n\n\n\n\nTIGECYCLINE\n\n\n\n\n\n\nImportant\n\n\n\nExperiments performed using freshly collected blood samples that use EDTA as an anticoagulant result in enhanced tigecycline activity.2 This phenomena was evident in preliminary experiments as shown in Figure 30.\n\n\nCode\nlibrary (readxl)\nlibrary (ggplot2)\ntheme_set(theme_bw())\nedta <- read_excel(\"datasets_single/edtaeffect.xlsx\")\nggplot(edta, aes(x=tig_s, y=tpos, color=tube, shape=tube)) + \n  geom_point(size=4, alpha = 0.7) + \nscale_x_continuous (name=\"Tigecycline conc, mg/L\") +\nscale_y_continuous(name=\"Tpos (hr)\", limits=c(4,25)) \n\n\n\n\n\nFigure 30: Effect of tigeycvcline concentrations on Tpos of K. pneumoniae using serum collected with and withouth EDTA\n\n\n\n\n\n\n\nKPC-A (MIC 0.75 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntig1 <- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit15 <- drda(tpos ~ tig_s, data=tig1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit15, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 31: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntig1 <- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit15 <- drda(tpos ~ tig_s, data=tig1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit15, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 28:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    26.21193 \n    22.64088 \n    29.78298 \n  \n  \n    0.25 \n    33.33312 \n    30.73822 \n    35.92801 \n  \n  \n    0.5 \n    42.38896 \n    40.56986 \n    44.20806 \n  \n  \n    0.75 \n    53.90507 \n    50.72689 \n    57.08325 \n  \n  \n    0.9 \n    68.54984 \n    60.64442 \n    76.45527 \n  \n  \n    0.95 \n    80.72308 \n    56.72937 \n    104.71680 \n  \n\n\n\n\n\n\n\n\nKPC-B (MIC 0.38 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntig2 <- read_excel(\"datasets_single/kpcb_tig.xlsx\")\nfit16 <- drda(tpos ~ tig_s, data=tig2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit16, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 32: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntig2 <- read_excel(\"datasets_single/kpca_tig.xlsx\")\nfit16 <- drda(tpos ~ tig_s, data=tig2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit16, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 29:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    26.21193 \n    22.64088 \n    29.78298 \n  \n  \n    0.25 \n    33.33312 \n    30.73822 \n    35.92801 \n  \n  \n    0.5 \n    42.38896 \n    40.56986 \n    44.20806 \n  \n  \n    0.75 \n    53.90507 \n    50.72689 \n    57.08325 \n  \n  \n    0.9 \n    68.54984 \n    60.64442 \n    76.45527 \n  \n  \n    0.95 \n    80.72308 \n    56.72937 \n    104.71680 \n  \n\n\n\n\n\n\n\n\nE. coli ATCC 25922 (MIC 0.125 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to tigecycline concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ntigecoli <- read_excel(\"datasets_single/ecoliatcc_tig.xlsx\")\nfittigecoli <- drda(tpos ~ tig_s, data=tigecoli, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fittigecoli, xlab = \"Tigecycline serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 33: Pharmacodynamic relationship of Tpos to tigecycline concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ntigecoli <- read_excel(\"datasets_single/ecoliatcc_tig.xlsx\")\nfittigecoli <- drda(tpos ~ tig_s, data=tigecoli, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fittigecoli, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 30:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    4.099751 \n    3.742536 \n    4.456966 \n  \n  \n    0.25 \n    6.123028 \n    5.816673 \n    6.429382 \n  \n  \n    0.5 \n    9.144816 \n    8.798910 \n    9.490721 \n  \n  \n    0.75 \n    13.657892 \n    12.976866 \n    14.338918 \n  \n  \n    0.9 \n    20.398226 \n    18.087056 \n    22.709396 \n  \n  \n    0.95 \n    26.796582 \n    18.484108 \n    35.109056 \n  \n\n\n\n\n\n\n\n\nE. coli ATCC 25922 (MIC 0.125 mg/L) protein binding\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nserum <- read_excel(\"datasets_single/ecoliatcc_tig_serum.xlsx\")\npbs <- read_excel(\"datasets_single/ecoliatcc_tig_pbs.xlsx\")\nfitserum <- drda(tpos ~ tig_s, serum, mean_function = \"loglogistic4\", max_iter = 1000)\nfitpbs <- drda(tpos ~ tig_s, pbs, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitserum, fitpbs, xlab = \"Tigecycline conc. (mg/L)\", ylab = \"Tpos\",cex = 0.9,legend = c(\"serum\", \"PBS\"))\n\n\n\n\n\nFigure 34: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nserum <- read_excel(\"datasets_single/ecoliatcc_tig_serum.xlsx\")\npbs <- read_excel(\"datasets_single/ecoliatcc_tig_pbs.xlsx\")\nfitserum <- drda(tpos ~ tig_s, serum, mean_function = \"loglogistic4\", max_iter = 1000)\nfitpbs <- drda(tpos ~ tig_s, pbs, mean_function = \"loglogistic4\", max_iter = 1000)\nedserum<-effective_dose(fitserum, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nedpbs<-effective_dose(fitpbs, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(edserum)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\n\n\n\n\n\n\nEstimate\n\n\nLower .95\n\n\nUpper .95\n\n\n\n\n\n\n0.1\n\n\n2.123423\n\n\n2.085530\n\n\n2.161317\n\n\n\n\n0.25\n\n\n3.333204\n\n\n3.299344\n\n\n3.367064\n\n\n\n\n0.5\n\n\n5.232235\n\n\n5.196848\n\n\n5.267621\n\n\n\n\n0.75\n\n\n8.213202\n\n\n8.144849\n\n\n8.281556\n\n\n\n\n0.9\n\n\n12.892521\n\n\n12.733520\n\n\n13.051522\n\n\n\n\n0.95\n\n\n17.519723\n\n\n17.041417\n\n\n17.998028\n\n\n\n\n\nFigure 35: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\nCode\nkbl(edpbs)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\n\n\n\n\n\n\nEstimate\n\n\nLower .95\n\n\nUpper .95\n\n\n\n\n\n\n0.1\n\n\n4.283286\n\n\n3.530962\n\n\n5.035611\n\n\n\n\n0.25\n\n\n6.954032\n\n\n6.402163\n\n\n7.505901\n\n\n\n\n0.5\n\n\n11.290059\n\n\n10.592118\n\n\n11.988000\n\n\n\n\n0.75\n\n\n18.329717\n\n\n17.061603\n\n\n19.597832\n\n\n\n\n0.9\n\n\n29.758793\n\n\n17.553542\n\n\n41.964045\n\n\n\n\n0.95\n\n\n41.376913\n\n\n0.000000\n\n\n90.646797\n\n\n\n\n\nFigure 36: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations\n\n\n\n\n\nCONCLUSIONS\n\n\n\n\nCEFTAZIDIME\n\nK. pneumoniae ATCC 700603 (MIC 12 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nceftaz_atcc <- read_excel(\"datasets_single/kpatcc_ceftazidime.xlsx\")\nfit_ceftazatcc <- drda(tpos ~ ctz_s, data=ceftaz_atcc, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit_ceftazatcc, xlab = \"Ceftazidime serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 37: Pharmacodynamic relationship of Tpos to ceftazidime concentrations against an ESBL producing ATCC strain\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nceftaz_atcc <- read_excel(\"datasets_single/kpatcc_ceftazidime.xlsx\")\nfit_ceftazatcc <- drda(tpos ~ ctz_s, data=ceftaz_atcc, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit_ceftazatcc, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 31:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    245.8990 \n    206.8423 \n    284.9557 \n  \n  \n    0.25 \n    295.0812 \n    265.6254 \n    324.5370 \n  \n  \n    0.5 \n    354.1003 \n    335.4615 \n    372.7390 \n  \n  \n    0.75 \n    424.9237 \n    398.3337 \n    451.5137 \n  \n  \n    0.9 \n    509.9125 \n    446.8074 \n    573.0176 \n  \n  \n    0.95 \n    577.2350 \n    434.9467 \n    719.5233 \n  \n\n\n\n\n\n\n\n\nK. pneumoniae KP-DAM (MIC 4 mg/L)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\nceftaz1 <- read_excel(\"datasets_single/kp_dam_ceftaz.xlsx\")\nfit17 <- drda(tpos ~ ctz_s, data=ceftaz1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fit17, xlab = \"Ceftazidime serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 38: Pharmacodynamic relationship of Tpos to ceftazidime concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\nceftaz1 <- read_excel(\"datasets_single/kp_dam_ceftaz.xlsx\")\nfit17 <- drda(tpos ~ ctz_s, data=ceftaz1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fit17, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 32:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    107.0276 \n    78.27442 \n    135.7809 \n  \n  \n    0.25 \n    136.4083 \n    116.29285 \n    156.5238 \n  \n  \n    0.5 \n    173.8544 \n    165.49765 \n    182.2112 \n  \n  \n    0.75 \n    221.5801 \n    196.00814 \n    247.1520 \n  \n  \n    0.9 \n    282.4071 \n    224.19394 \n    340.6202 \n  \n  \n    0.95 \n    333.0621 \n    230.10196 \n    436.0223 \n  \n\n\n\n\n\n\n\n\nCONCLUSIONS\n\n\n\n\nCIPROFLOXACIN\n\nK. pneumoniae WT (MIC <= 0.06)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncipro1 <- read_excel(\"datasets_single/kpwt_cipro_powder.xlsx\")\nfitcipro1 <- drda(tpos ~ cipro_s, data=cipro1, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcipro1, xlab = \"Ciprofloxacin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 39: Pharmacodynamic relationship of Tpos to ceftazidime concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncipro1 <- read_excel(\"datasets_single/kpwt_cipro_powder.xlsx\")\nfitcipro1 <- drda(tpos ~ cipro_s, data=cipro1, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitcipro1, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 33:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    0.2429975 \n    0.1876993 \n    0.2982956 \n  \n  \n    0.25 \n    0.3259756 \n    0.2760740 \n    0.3758772 \n  \n  \n    0.5 \n    0.4372888 \n    0.3916951 \n    0.4828826 \n  \n  \n    0.75 \n    0.5866130 \n    0.5247666 \n    0.6484594 \n  \n  \n    0.9 \n    0.7869281 \n    0.6566179 \n    0.9172382 \n  \n  \n    0.95 \n    0.9609705 \n    0.7089475 \n    1.2129934 \n  \n\n\n\n\n\n\n\n\nKPC B (MIC <= 0.38)\n\n\nCode\n## a four-parameter logistic regression model is fit to ceftazidime concentrations to estimated PD parameters\nlibrary (readxl)\nlibrary(drda)\ncipro2 <- read_excel(\"datasets_single/kpcb_cipro_powder.xlsx\")\nfitcipro2 <- drda(tpos ~ cipro_s, data=cipro2, mean_function = \"loglogistic4\", max_iter = 1000)\nplot(fitcipro2, xlab = \"Ciprofloxacin serum conc. (mg/L)\", ylab = \"Tpos (hr)\")\n\n\n\n\n\nFigure 40: Pharmacodynamic relationship of Tpos to ceftazidime concentrations\n\n\n\n\n\n\nCode\n## Analysis is repeated to produce a table reporting estimated EC10-EC95 parameter estimates plus 95% CI \nlibrary (readxl)\nlibrary(drda)\nlibrary(broom)\nlibrary(kableExtra)\ncipro2 <- read_excel(\"datasets_single/kpcb_cipro_powder.xlsx\")\nfitcipro2 <- drda(tpos ~ cipro_s, data=cipro2, mean_function = \"loglogistic4\", max_iter = 1000)\ned<-effective_dose(fitcipro2, y = c(0.10,0.25,0.50,0.75,0.90,0.95))\nkbl(ed)%>%\nkable_paper(\"hover\", full_width = F, position = \"left\")\n\n\n\n\nTable 34:  Pharmacodynamic estimates \n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    7.164090 \n    6.590145 \n    7.738036 \n  \n  \n    0.25 \n    8.982345 \n    8.565516 \n    9.399174 \n  \n  \n    0.5 \n    11.262075 \n    10.893533 \n    11.630618 \n  \n  \n    0.75 \n    14.120404 \n    13.417518 \n    14.823290 \n  \n  \n    0.9 \n    17.704179 \n    16.211318 \n    19.197041 \n  \n  \n    0.95 \n    20.648354 \n    17.657499 \n    23.639209 \n  \n\n\n\n\n\n\n\n\nCONCLUSIONS"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy",
    "href": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy",
    "title": "The Acute Website",
    "section": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy",
    "text": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy\n\n\n\n\n\n\nPrinciple Investigator: Irene Zaghi, M.D.\nSupervisors:\n\nRussell E. Lewis, Pharm.D., University of Padua\nMonica Cricca, M.D., Ph.D., University of Bologna\nVittorio Sambri, M.D., Ph.D., Univeristy of Bologna\n\n\n\nJanuary 20, 2023"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\nImage: Irene Zaghi, M.D."
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-1",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-1",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\n\n(Theuretzbacher 2012; Roberts et al. 2014)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-2",
    "href": "slides/ACUTE_SLIDES.html#antibiotic-dosing-is-an-uncertain-science-2",
    "title": "The Acute Website",
    "section": "Antibiotic dosing is an uncertain science",
    "text": "Antibiotic dosing is an uncertain science\n\n\n\n\n\n\n\n\n(Theuretzbacher 2012; Roberts et al. 2014)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#how-can-dosing-uncertainty-be-managed",
    "href": "slides/ACUTE_SLIDES.html#how-can-dosing-uncertainty-be-managed",
    "title": "The Acute Website",
    "section": "How can dosing uncertainty be managed?",
    "text": "How can dosing uncertainty be managed?\n\n\n\n\n\n\n\n(Roberts et al. 2014)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance",
    "href": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance",
    "title": "The Acute Website",
    "section": "Dosing uncertainty at the dawn of penicillin resistance",
    "text": "Dosing uncertainty at the dawn of penicillin resistance\n\n\n\n\n\n\n\n(Schlichter and Mac Lean 1947)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance-1",
    "href": "slides/ACUTE_SLIDES.html#dosing-uncertainty-at-the-dawn-of-penicillin-resistance-1",
    "title": "The Acute Website",
    "section": "Dosing uncertainty at the dawn of penicillin resistance",
    "text": "Dosing uncertainty at the dawn of penicillin resistance\n\n\n\n“It was felt that there was a need of some definite basis for determining adequate therapy for each specific infectious organism involved…”\n\n\n“Current methods in general use all depend on indirect comparisons (MICs, measurement of penicillin blood levels). In patients with more resistant organisms, it has not been demonstrated that this is the proper approach…”\n\n\n“…It occurred to us that a more satisfactory method of outlining adequate therapy in resistant organisms might be based on the action of the patient’s own serum during penicillin administration.”\n\n\n\n(Schlichter and Mac Lean 1947)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#serum-bactericidal-test-sbt",
    "href": "slides/ACUTE_SLIDES.html#serum-bactericidal-test-sbt",
    "title": "The Acute Website",
    "section": "Serum bactericidal test (SBT)",
    "text": "Serum bactericidal test (SBT)\n\n\n\n\n\n\n\n(CLSI 1999; Zaghi et al. 2020)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#sbts-correlate-with-antibiotic-pkpd",
    "href": "slides/ACUTE_SLIDES.html#sbts-correlate-with-antibiotic-pkpd",
    "title": "The Acute Website",
    "section": "SBTs correlate with antibiotic PK/PD",
    "text": "SBTs correlate with antibiotic PK/PD\n\n\n\n\n\n\n\n(Zaghi et al. 2020)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#potential-clinical-utility-of-sbts",
    "href": "slides/ACUTE_SLIDES.html#potential-clinical-utility-of-sbts",
    "title": "The Acute Website",
    "section": "Potential clinical utility of SBTs",
    "text": "Potential clinical utility of SBTs\nIndividual patient-level diagnostic meta-analysis (1947-2020)\n\n\n\n\n\nPrognostic performance similar or better than current susceptibility breakpoints\n\n\n(Zaghi et al. 2020)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#sbt-advantages",
    "href": "slides/ACUTE_SLIDES.html#sbt-advantages",
    "title": "The Acute Website",
    "section": "SBT advantages",
    "text": "SBT advantages\n\n\nOnly microbiological test that accounts for both antibiotic PK and PD\nTheoretically accounts for protein binding changes\nCan detect synergistic or antagonistic interactions"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#why-were-sbts-abandoned",
    "href": "slides/ACUTE_SLIDES.html#why-were-sbts-abandoned",
    "title": "The Acute Website",
    "section": "Why were SBTs abandoned?",
    "text": "Why were SBTs abandoned?\n\n\nInsufficent standardization despite published methods (CLSI M21-A, last updated 1999)\nPoor inter-laboratory reproducibility\nLabour-intensive to perform\nLack of perceived need in 1990s (reliably bactericidal antibiotics)\nDelay in results reporting (48-72 hours with patients isolate)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#i-read-your-sbt-review-and-have-a-suggestion",
    "href": "slides/ACUTE_SLIDES.html#i-read-your-sbt-review-and-have-a-suggestion",
    "title": "The Acute Website",
    "section": "“I read your SBT review and have a suggestion…”",
    "text": "“I read your SBT review and have a suggestion…”\nUse continuously-monitored bloodculture systems Time-to-positivity (Tpos) to measure bactericidal activity\nConcept: The assay measures the time taken for a standardized bacterial inoculum to “grow through” the antimicrobial activity in the patient’s serum under defined conditions.\n\n\n\n\n\n\n\n\nA short Tpos would indicate inadequate antimicrobial activity and should predict a worse outcome\nA long Tpos is evidence of adequate antimicrobial activity and should predict a good outcome"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#blood-culture-tpos-measures-bacterial-inoculum-and-antimicrobial-pharmacokinetics",
    "href": "slides/ACUTE_SLIDES.html#blood-culture-tpos-measures-bacterial-inoculum-and-antimicrobial-pharmacokinetics",
    "title": "The Acute Website",
    "section": "Blood culture Tpos measures bacterial inoculum and antimicrobial pharmacokinetics",
    "text": "Blood culture Tpos measures bacterial inoculum and antimicrobial pharmacokinetics\n\n\nA “critical” Tpos result could be reported in < 12 hours!\n\n\n\n\n\n\n\n\n(Kaltsas, Want, and Cohen 2005; Jerwood, Hankins, and Cohen 2012)"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy-1",
    "href": "slides/ACUTE_SLIDES.html#adapting-bloodculture-systems-to-monitor-antimicrobial-efficacy-1",
    "title": "The Acute Website",
    "section": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy",
    "text": "Adapting Bloodculture Systems to Monitor Antimicrobial Efficacy\n\n\n\n\nSpecific Aim# 1: Establish the quantitative relationship in vitro between Tpos and carbapenamase-producing Enterobacterales (CPE) and define antibiotic concentration-effect relationships\nSpecific Aim#2: Pilot observational clinical study in 20 septic patients undergoing treatment for CPE to explore how early Tpos results with “indicator” isolates correlate with individual antibiotic PK/PD targets"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-correlates-with-inoculum",
    "href": "slides/ACUTE_SLIDES.html#tpos-correlates-with-inoculum",
    "title": "The Acute Website",
    "section": "Tpos correlates with inoculum",
    "text": "Tpos correlates with inoculum\n\nK. pneumoniaeE. coliA. baumaniiP. aeruginosa\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nR2 = 0.96-0.99"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-can-descriminate-between-susceptible-and-resistant-pathogens",
    "href": "slides/ACUTE_SLIDES.html#tpos-can-descriminate-between-susceptible-and-resistant-pathogens",
    "title": "The Acute Website",
    "section": "Tpos can descriminate between susceptible and resistant pathogens",
    "text": "Tpos can descriminate between susceptible and resistant pathogens\n\n\n\n\n\n\n\nKPC_B MIC 1.0 mg/L, KPC_NDM MIC > 256 mg/L; data fit by Loess"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#pharmacodynamic-relationship-of-tpos-against-k.-pneumoniae-atcc-700603-0.75-mgl",
    "href": "slides/ACUTE_SLIDES.html#pharmacodynamic-relationship-of-tpos-against-k.-pneumoniae-atcc-700603-0.75-mgl",
    "title": "The Acute Website",
    "section": "Pharmacodynamic relationship of Tpos against  K. pneumoniae ATCC 700603 (0.75 mg/L)",
    "text": "Pharmacodynamic relationship of Tpos against  K. pneumoniae ATCC 700603 (0.75 mg/L)\n\nCeftazidime-avibactam4:1 ratioFixed 4 mg/L\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    23.87874 \n    19.31716 \n    28.44033 \n  \n  \n    0.25 \n    26.93812 \n    24.06902 \n    29.80723 \n  \n  \n    0.5 \n    30.38948 \n    29.11007 \n    31.66888 \n  \n  \n    0.75 \n    34.28302 \n    31.38838 \n    37.17767 \n  \n  \n    0.9 \n    38.67541 \n    33.84814 \n    43.50268 \n  \n  \n    0.95 \n    41.98020 \n    33.98412 \n    49.97627 \n  \n\n\n\n\n\n\n\n\n\n\n\n \n  \n      \n    Estimate \n    Lower .95 \n    Upper .95 \n  \n \n\n  \n    0.1 \n    8.099087 \n    7.038485 \n    9.159689 \n  \n  \n    0.25 \n    9.235833 \n    8.728989 \n    9.742676 \n  \n  \n    0.5 \n    10.532127 \n    10.149119 \n    10.915134 \n  \n  \n    0.75 \n    12.010361 \n    10.856802 \n    13.163921 \n  \n  \n    0.9 \n    13.696074 \n    11.685276 \n    15.706872 \n  \n  \n    0.95 \n    14.975851 \n    12.415855 \n    17.535846"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#inoculum-effects-observed-with-pd-relationship-measured-by-tpos",
    "href": "slides/ACUTE_SLIDES.html#inoculum-effects-observed-with-pd-relationship-measured-by-tpos",
    "title": "The Acute Website",
    "section": "Inoculum effects observed with PD relationship measured by Tpos",
    "text": "Inoculum effects observed with PD relationship measured by Tpos"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "href": "slides/ACUTE_SLIDES.html#tpos-demonstrates-a-consistent-relationship-across-different-antibiotics-and-isolates-with-different-mics",
    "title": "The Acute Website",
    "section": "Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs",
    "text": "Tpos demonstrates a consistent relationship across different antibiotics and isolates with different MICs"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#comparison-of-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#comparison-of-indicator-isolates",
    "title": "The Acute Website",
    "section": "Comparison of indicator isolates",
    "text": "Comparison of indicator isolates\n\nFigure 1: Pharmacodynamic relationship of Tpos to ceftazidime/avibactam concentrations"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#combination-therapy",
    "href": "slides/ACUTE_SLIDES.html#combination-therapy",
    "title": "The Acute Website",
    "section": "Combination therapy",
    "text": "Combination therapy"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#ceftazidime-avibactam-gentamicin",
    "href": "slides/ACUTE_SLIDES.html#ceftazidime-avibactam-gentamicin",
    "title": "The Acute Website",
    "section": "Ceftazidime-avibactam + gentamicin",
    "text": "Ceftazidime-avibactam + gentamicin"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#how-could-tpos-be-used-clinically",
    "href": "slides/ACUTE_SLIDES.html#how-could-tpos-be-used-clinically",
    "title": "The Acute Website",
    "section": "How could Tpos be used clinically",
    "text": "How could Tpos be used clinically"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#could-tpos-be-used-with-indicator-isolates",
    "href": "slides/ACUTE_SLIDES.html#could-tpos-be-used-with-indicator-isolates",
    "title": "The Acute Website",
    "section": "Could Tpos be used with “indicator” isolates?",
    "text": "Could Tpos be used with “indicator” isolates?"
  },
  {
    "objectID": "slides/ACUTE_SLIDES.html#references",
    "href": "slides/ACUTE_SLIDES.html#references",
    "title": "The Acute Website",
    "section": "References",
    "text": "References\n\n\n\n\n\n\n\nCLSI. 1999. Methodology for the Serum Bactericidal Test; Approved Guideline M21-A.\n\n\nJerwood, Susannah, Matthew Hankins, and Jon Cohen. 2012. “A Pilot Clinical Trial to Evaluate a Novel Time-to-Positivity Assay to Measure the Effectiveness of Antibiotic Therapy for Septic Patients in Intensive Care.” Journal of Critical Care 27 (3): 320.e1–5. https://doi.org/10.1016/j.jcrc.2011.06.009.\n\n\nKaltsas, P, S Want, and J Cohen. 2005. “Development of a Time-to-Positivity Assay as a Tool in the Antibiotic Management of Septic Patients.” Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 11 (2): 109–14. https://doi.org/10.1111/j.1469-0691.2004.01054.x.\n\n\nRoberts, Jason A, Mohd H Abdul-Aziz, Jeffrey Lipman, Johan W Mouton, Alexander A Vinks, Timothy W Felton, William W Hope, et al. 2014. “Individualised Antibiotic Dosing for Patients Who Are Critically Ill: Challenges and Potential Solutions.” The Lancet Infectious Diseases 14 (6): 498–509. https://doi.org/10.1016/s1473-3099(14)70036-2.\n\n\nSchlichter, J. G., and H. Mac Lean. 1947. “A Method of Determining the Effective Therapeutic Level in the Treatment of Subacute Bacterial Endocarditis with Penicillin; a Preliminary Report.” American Heart Journal 34 (2): 209–11. https://doi.org/10.1016/0002-8703(47)90289-5.\n\n\nTheuretzbacher, Ursula. 2012. “Pharmacokinetic and Pharmacodynamic Issues for Antimicrobial Therapy in Patients with Cancer.” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 54 (12): 1785–92. https://doi.org/10.1093/cid/cis210.\n\n\nZaghi, I., P. Gaibani, C. Campoli, M. Bartoletti, M. Giannella, S. Ambretti, P. Viale, and R. E. Lewis. 2020. “Serum Bactericidal Titres for Monitoring Antimicrobial Therapy: Current Status and Potential Role in the Management of Multidrug-Resistant Gram-negative Infections.” Clinical Microbiology and Infection 26 (10): 1338–44. https://doi.org/10.1016/j.cmi.2020.04.036."
  },
  {
    "objectID": "Publications.html",
    "href": "Publications.html",
    "title": "Publications",
    "section": "",
    "text": "Is timing everything?\n\nA Bayesian meta-analysis of the prognostic and diagnostic utility of bloodculture time-to-positivity (TTP) and differential time-to positivity (DTP) for bloodstream infections\nClick here for the poster\nPresented at 2022 ESCMID Meeting, Lisbon\nAbstract #01824"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "Background",
    "section": "",
    "text": "The ACUTE project proposes to develop time-to positivity (Tpos) - a commonly reported index from continuously monitored bloodculture systems used in clinical microbiology laboratories- as a surrogate pharmacodynamic marker for monitoring antibiotic therapy of multidrug resistant (MDR) gram-negative bacteria.\nThe project will generate fundamental knowledge of how Tpos correlates with established pharmacodynamic indices for antibiotics (e.g. AUC/MIC, %T>MIC). Proof of principle experiments will be conducted with ceftazidime-avibactam monotherapy, and combination antibiotic regimens, that are tested both in vitro, and then in sera from patients undergoing treatment for KPC-carbapenemase producing Klebsiella pneumoniae (KPC-Kp). \n\n\n\n\n\n\n\nThe objectives of this project will be accomplished through two specific aims.\n\nThe first specific aim will establish the quantitative relationship between Tpos and representative KPC-Kp strains in the absence and presence of clinically-relevant antibiotic exposures.\nThe second specific aim will measure Tpos using sera from 20 critically-ill patients receiving ceftazidime-avibactam treatment for KPC-KP bloodstream infections using “indicator” strains or the patient’s own isolate. Tpos results will be correlated with blood concentration-time courses of ceftazidime and avibactam and PK/PD target attainment (free drug T>MIC ) simulated for each patient using Bayesian estimates of individual PK parameters from population pharmacokinetic models and LC/MS/MS analysis of ceftazidime-avibactam drug concentrations in serum.\n\nThis study will form the basis for the broader development and validation of Tpos as a surrogate pharmacodynamic (PD) biomarker for monitoring antimicrobial activity of antibiotic monotherapy and combination therapy for Gram-negative infections."
  },
  {
    "objectID": "Summary.html",
    "href": "Summary.html",
    "title": "ECCMID 2023 ABSTRACT (Submitted)",
    "section": "",
    "text": "Pharmacodynamics of ceftazidime-avibactam monotherapy and combination regimens against carbapenemase-producing Klebsiella pneumoniae measured by bloodculture system time to positivity (Tpos)\nIrene Zaghi¹, Monica Cricca¹‐², Vittorio Sambri¹‐², Jason Roberts³, Russell Lewis⁴\n¹ Laboratorio Unico della AUSL della Romagna, in Pievesestina di Cesena, Italy\n² Department of Diagnostic and Experimental Medicine, University of Bologna, Italy\n³ The University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia\n⁴ Department of Medical and Surgical Sciences, University of Bologna, Italy\nBackground: Time-to-positivity is a commonly reported index in bloodculture systems that can be adapted to measure bactericidal activity in the patient’s bloodstream during antibiotic therapy. We examined how simulated serum concentrations of ceftazidime-avibactam (CZA),meropenem (MEM), gentamicin(GEN), tigecycline (TGC), colistin (CST) or aztreonam (ATM) alone, or in combination, impacted Tpos measured against test inocula of KPC and NDM-carbapenemase producing K. pneumoniae (KP).\nMaterials and Methods: Experiments were carried out with two KPC-2 and one NDM-2 carbapenemase-producing KP isolate. We first analyzed how Tpos changes with inoculum (3x101-3x108 ) prepared in standard BacT/ALERT aerobic bloodculture bottles without antibiotic inactivating matrix. We then inoculated 1 mL of human serum containing antibiotic concentrations/combinations simulating a range of expected human exposures into bottles containing a fixed inoculum (1x104 CFU/mL) of test isolates. The relationship of Tpos vs. antibiotic concentrations was fitted to 4-parameter logistic regression model to estimate EC50/EC90. For combinations, a predicted null-response (Bliss-independence) interaction model was compared to Tpos observed with the antibiotic combination array to identify synergistic or antagonistic interactions.\nResults: In the absence of antibiotic-containing serum, all isolates demonstrated a linear relationship between Tpos of 9.4-10.8h to 4.5-5.2h over an inoculum range spanning 3x101 to 3x108 CFU/mL. A consistent dose-response relationship between Tpos and serum antibiotic exposures was observed for all antibiotics with the EC50 Tpos of ~16 hr evident at 1xMIC (Fig 1). Combination experiments revealed prolongation of Tpos for most antibiotic combinations (Table, Fig 2a) with the greatest improvement in Tpos observed with CZA + ATM against the NDM-producing KP (Table, Fig 2b.)\n\n\n\nFigure 1. Relationship between Tpos and Antibiotic Conc/MIC\n\n\n\n\n\nFigure 2. Bliss independence interaction model for antibiotic combinations\n\n\n\nTable 1. Mean change in Tpos for combination therapy versus predicted null response from Bliss Independence model\n\n\n\n\n\n\n\nAntibiotic combination\nStrain\nMean Tpos change (hr) from predicted null response surface (95% CI)\n\n\nCZA + GENT\nKP_A (KPC)\n+ 5.68 (5.09-6.53)\n\n\nCZA + GENT\nKP_B (KPC)\n+ 3.05 (2.16-4.03)\n\n\nCZA + COL\nKP_B (KPC)\n+ 2.31 (1.40-3.20)\n\n\nCZA + TGC\nKP_B (KPC)\n+ 1.66 (0.72-2.73)\n\n\nCZA + ATM\nKP_NDM\n+ 10.33 (10.32-10.34)\n\n\n\nConclusions: Tpos was a robust and reproducible indicator of antimicrobial activity in serum that is capable of detecting synergistic antibiotic interactions. Further test optimization could support the use of this simple monitoring approach of antimicrobial activity in patient serum."
  },
  {
    "objectID": "Workpackage2.html",
    "href": "Workpackage2.html",
    "title": "Workpackage 2",
    "section": "",
    "text": "Code\nlibrary(PKPDsim)\nlibrary(PKPDplot)\nlibrary (ggplot2)\npk1 <- new_ode_model(model = \"pk_2cmt_iv\") # ceftazidime\npk2 <- new_ode_model(model = \"pk_2cmt_iv\") # avibactam\np <- list(\n  CL = 6.95,\n  V  = 10.5,\n  Q  = 31.5,\n  V2 = 7.57)\n\np2 <- list(\n  CL = 10.2,\n  V  = 11.1,\n  Q  = 5.44,\n  V2 = 6.91)\nn <- 100\n\nomega <- cv_to_omega(list(CL=0.423, V=1.05, Q=0.315, V2=1.10))\n\nomega2 <- cv_to_omega(list(CL=0.591, V=1.07, Q=1.22, V2=6.91))\nr1 <- new_regimen(\n  amt = 2000,\n  interval = 8,\n  n = 5,\n  type = \"infusion\",\n  t_inf = c(2,2,2,2,2)\n)\n\nr2 <- new_regimen(\n  amt = 500,\n  interval = 8,\n  n = 5,\n  type = \"infusion\",\n  t_inf = c(2,2,2,2,2)\n)\ndat <- sim(\n  ode = pk1,\n  parameters = p,\n  omega = omega,\n  n_ind = 20,\n  res_var = list(prop=0.1, add=7.5),\n  regimen = r1, \n  covariates = list(\"SCR\" = new_covariate(value = 80)), output_include = list(parameters=TRUE, variable=TRUE, covariates=TRUE)\n)\n\ndat2 <- sim(\n  ode = pk2,\n  parameters = p2,\n  omega = omega2,\n  n_ind = 20,\n  res_var = list(prop=0.17, add=0.5),\n  regimen = r2, \n  covariates = list(\"SCR\" = new_covariate(value = 80)), output_include = list(parameters=TRUE, variable=TRUE, covariates=TRUE)\n)\n\nplot(dat, show_population = list(obs = TRUE, spaghetti = FALSE, ci = TRUE, \n                                 median =TRUE, regimen = TRUE), ci = c(0.05, 0.95))"
  },
  {
    "objectID": "Workpackage1_combination.html",
    "href": "Workpackage1_combination.html",
    "title": "Workpackage 1-Combinations",
    "section": "",
    "text": "The activity of combination ceftazidime/avibactam (4 to 1 ratio from commercial formulation) plus gentamicin (0-4 mg/L) was tested against Klebsiella pneumonia KPCB strain in 5 replicate experiments using an array of test concentrations.\n\n\n\nTest array\n\n\nThe effect of the antibiotic combinations Tpos combination was analyzed using a Bliss Independence Model of drug interaction using a workflow described for the synergy analysis using the BIGL package.1\nThe first step of the fitting procedure analyzed marginal data only, i.e.-those observations within the experiment where one of the compounds is dosed at zero. For each compound the corresponding marginal doses are modelled using a 4-parameter logistic model\nThe marginal models will be estimated together using non-linear least squares estimation procedure. A simple sum-of-squared-residuals minimization driven by a default Nelder-Mead algorithm from optim minimizer was used.\nPresence of synergistic or antagonistic effects was formalized by means of the meanR and maxR test. meanR test evaluates how the predicted response surface based on a specified null model differs from the observed one. If the null hypothesis is rejected, this test suggests that at least some dose combinations may exhibit synergistic or antagonistic behaviour. The meanR test is not designed to pinpoint which combinations produce these effects nor what type of deviating effect is present.\nmaxR test allows to evaluate presence of synergistic/antagonistic effects for each dose combination and as such provides a point-by-point classification.\n\n\n\n\n\n\n\n\nThe results shown in ?@fig-10wp2 demonstrated that CTZ/AVI + gentamicin is broadly synergistic over the range of tested concentrations, with an average 4.29 hr increase (95% CI 2.65-6.46) in Tpos versus the predicted null interactive response of ceftazidime-avibactam and gentamicin alone.\n\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_gent_kpcb <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/caz_gent_kpcb.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit <- fitMarginals(caz_gent_kpcb, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"GENT\"))\nsummary(marginalFit)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime and gentamicin, minimum constrained at 9 hrs and maximum contrastined at 24 hours\nplot(marginalFit) + ggtitle(paste(\"Ceftazidime/Avibactam + Gentamicin\"))\nrs <- fitSurface(caz_gent_kpcb, marginalFit,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n3.0477 [2.2481, 4.007]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n19.95_19.95   6.9764 2.0572 11.8957  Syn\n39.9_19.95    9.4952 5.8848 13.1056  Syn\n79.8_19.95    6.6173 2.5914 10.6432  Syn\n79.8_4.9875   9.3826 2.0492 16.7161  Syn\n79.8_9.975    8.9935 6.0041 11.9828  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   5   0    15\n\n\nCode\nplot(rs, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 1: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\nCode\n## mean R statistic evaluates how the test evaluates how the predicted response surface based on a specified null model differs from the observed one. If the null hypothesis is rejected, this test suggests that at least some dose combinations may exhibit synergistic or antagonistic behaviour. The meanR test is not designed to pinpoint which combinations produce these effects nor what type of deviating effect is present.\nmeanR_N <-fitSurface(caz_gent_kpcb, marginalFit, statistic=\"meanR\",CP=rs$CP, B.B=20, parallel = FALSE)\n\n# maxR test allows to evaluate presence of synergistic/antagonistic effects for each dose combination and as such provides a point-by-point classification.\nmaxR_N <- fitSurface(caz_gent_kpcb, marginalFit,\n                     statistic = \"maxR\", CP = rs$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_B <- fitSurface(caz_gent_kpcb, marginalFit,\n                     statistic = \"maxR\", CP = rs$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_both <- rbind(summary(maxR_N$maxR)$totals,\n                   summary(maxR_B$maxR)$totals)\n\ncontour(maxR_B,\n         ## colorPalette = c(\"blue\", \"black\", \"black\", \"red\"),\n        main = paste0(\" Ceftazidime/Avibactam + Gentamicin\"),\n        scientific = TRUE, digits = 3, cutoff = cutoff)\n\nplotConfInt(maxR_B, color =\"effect-size\")\n\nrsh <- fitSurface(caz_gent_kpcb, marginalFit,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(15,87) = 22.8701 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2      absR p-value call\n19.95_19.95 19.95 19.9500  4.641679   1e-04  Syn\n39.9_19.95  39.90 19.9500 11.185995  <2e-16  Syn\n79.8_19.95  79.80 19.9500  8.325151  <2e-16  Syn\n79.8_4.9875 79.80  4.9875  4.136343 0.00111  Syn\n79.8_9.975  79.80  9.9750 10.250631  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   5   0    15\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n3.2336 [2.1092, 4.1451]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n19.95_19.95   6.9765 3.1071 10.8459  Syn\n39.9_19.95    9.5042 6.8960 12.1125  Syn\n79.8_19.95    9.3826 6.3518 12.4135  Syn\n79.8_4.9875   9.3826 3.1616 15.6037  Syn\n79.8_9.975    8.9938 6.5390 11.4485  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   5   0    15\n\n\nCode\nrsb <- fitSurface(caz_gent_kpcb, marginalFit, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              9.271 13.756\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.327\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(15,87) = 17.7733 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2      absR p-value call\n19.95_19.95 19.95 19.9500  4.116661 0.00138  Syn\n39.9_19.95  39.90 19.9500 10.126517  <2e-16  Syn\n79.8_19.95  79.80 19.9500  4.000327 0.00231  Syn\n79.8_4.9875 79.80  4.9875  4.149137 0.00122  Syn\n79.8_9.975  79.80  9.9750 10.372249  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   5   0    15\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n3.0477 [2.1585, 4.0323]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n19.95_19.95   6.9764 2.0906 11.8623  Syn\n39.9_19.95    9.4952 6.1100 12.8804  Syn\n79.8_19.95    6.6173 2.6989 10.5357  Syn\n79.8_4.9875   9.3826 1.6980 17.0673  Syn\n79.8_9.975    8.9935 5.9019 12.0850  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   5   0    15\n\n\n\n\n\nFigure 2: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 3: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 4: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\nThe activity of combination ceftazidime/avibactam (4 to 1 ratio from analytical powder) plus gentamicin was tested against Klebsiella pneumonia KPC_A strain in 5 replicate experiments using the same methodology.\nResults are shown in ?@fig-11wp2\n\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_gent_kpca2 <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kpca_gent_caz.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit2 <- fitMarginals(caz_gent_kpca2, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"GENT\"))\nsummary(marginalFit2)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime and gentamicin, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit2) + ggtitle(paste(\"Ceftazidime/Avibactam + Gentamicin\"))\nrs2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs2)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n5.5514 [4.9162, 6.2709]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower   upper call\n1.9_0.95     6.6045 4.4936  8.7154  Syn\n1.9_1.425   10.2930 2.9105 17.6755  Syn\n2.85_0.475  13.3292 6.4187 20.2398  Syn\n2.85_0.95   13.1710 8.1373 18.2046  Syn\n2.85_1.425   9.4954 2.1260 16.8648  Syn\n3.8_0.0095   7.7899 0.7970 14.7828  Syn\n3.8_0.0285   7.7899 0.7970 14.7828  Syn\n3.8_0.2375   7.2899 3.4309 11.1488  Syn\n3.8_0.475    7.5611 4.3937 10.7285  Syn\n3.8_0.95     7.6972 4.8569 10.5375  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  10   0    18\n\n\nCode\nplot(rs2, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 5: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\nCode\n## mean R statistic evaluates how the test evaluates how the predicted response surface based on a specified null model differs from the observed one. If the null hypothesis is rejected, this test suggests that at least some dose combinations may exhibit synergistic or antagonistic behaviour. The meanR test is not designed to pinpoint which combinations produce these effects nor what type of deviating effect is present.\nmeanR_N2 <-fitSurface(caz_gent_kpca2, marginalFit2, statistic=\"meanR\",CP=rs2$CP, B.B=20, parallel = FALSE)\n\n# maxR test allows to evaluate presence of synergistic/antagonistic effects for each dose combination and as such provides a point-by-point classification.\nmaxR_N2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                     statistic = \"maxR\", CP = rs2$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_B2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                     statistic = \"maxR\", CP = rs2$CP, B.B = 20,\n                     parallel = FALSE)\nmaxR_both2 <- rbind(summary(maxR_N2$maxR)$totals,\n                   summary(maxR_B2$maxR)$totals)\n\ncontour(maxR_B2,\n         ## colorPalette = c(\"blue\", \"black\", \"black\", \"red\"),\n        main = paste0(\" Ceftazidime/Avibactam + Gentamicin\"),\n        scientific = TRUE, digits = 3, cutoff = cutoff)\n\nplotConfInt(maxR_B2, color =\"effect-size\")\n\nrsh2 <- fitSurface(caz_gent_kpca2, marginalFit2,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh2)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(18,150) = 33.6972 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n             d1     d2      absR p-value call\n1.9_0.95   1.90 0.9500 13.591463  <2e-16  Syn\n1.9_1.425  1.90 1.4250  5.561332   1e-05  Syn\n1.9_1.9    1.90 1.9000  4.861305   2e-05  Syn\n2.85_0.475 2.85 0.4750  7.732139  <2e-16  Syn\n2.85_0.95  2.85 0.9500 10.656374  <2e-16  Syn\n2.85_1.425 2.85 1.4250  5.561332   1e-05  Syn\n3.8_0.0095 3.80 0.0095  3.341910 0.01935  Syn\n3.8_0.0285 3.80 0.0285  3.341910 0.01935  Syn\n3.8_0.2375 3.80 0.2375  4.845663   2e-05  Syn\n3.8_0.475  3.80 0.4750  6.340654  <2e-16  Syn\n3.8_0.95   3.80 0.9500  7.681099  <2e-16  Syn\n3.8_1.9    3.80 1.9000  3.825904 0.00349  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  12   0    18\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n5.6804 [5.0922, 6.5342]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower   upper call\n1.9_0.95     6.6547 4.4460  8.8634  Syn\n1.9_1.425   10.3292 2.6111 18.0473  Syn\n2.85_0.475  13.3296 5.9540 20.7052  Syn\n2.85_0.95   13.3296 7.9390 18.7202  Syn\n2.85_1.425  10.3292 2.6111 18.0473  Syn\n3.8_0.0095   7.7899 0.2695 15.3103  Syn\n3.8_0.0285   7.7899 0.2695 15.3103  Syn\n3.8_0.2375   7.2899 2.9835 11.5963  Syn\n3.8_0.475    7.5613 3.9399 11.1827  Syn\n3.8_0.95     7.7899 4.4820 11.0978  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  10   0    18\n\n\nCode\nrsb2 <- fitSurface(caz_gent_kpca2, marginalFit2, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb2)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(18,150) = 35.2265 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n             d1     d2      absR p-value call\n1.9_0.95   1.90 0.9500 13.202805  <2e-16  Syn\n1.9_1.425  1.90 1.4250  5.658116  <2e-16  Syn\n1.9_1.9    1.90 1.9000  4.869663   2e-05  Syn\n2.85_0.475 2.85 0.4750  7.867521  <2e-16  Syn\n2.85_0.95  2.85 0.9500 10.492628  <2e-16  Syn\n2.85_1.425 2.85 1.4250  4.577642 0.00013  Syn\n3.8_0.0095 3.80 0.0095  3.809688 0.00379  Syn\n3.8_0.0285 3.80 0.0285  3.809688 0.00379  Syn\n3.8_0.2375 3.80 0.2375  5.933555  <2e-16  Syn\n3.8_0.475  3.80 0.4750  7.822571  <2e-16  Syn\n3.8_0.95   3.80 0.9500  8.960655  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  11   0    18\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n5.5514 [4.7906, 6.18]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower   upper call\n1.9_0.95     6.6045 4.4249  8.7841  Syn\n1.9_1.425   10.2930 2.6842 17.9018  Syn\n2.85_0.475  13.3292 6.1146 20.5438  Syn\n2.85_0.95   13.1710 7.9058 18.4361  Syn\n2.85_1.425   9.4954 1.8632 17.1277  Syn\n3.8_0.0095   7.7899 0.5259 15.0539  Syn\n3.8_0.0285   7.7899 0.5259 15.0539  Syn\n3.8_0.2375   7.2899 3.2980 11.2818  Syn\n3.8_0.475    7.5611 4.2940 10.8282  Syn\n3.8_0.95     7.6972 4.7761 10.6183  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  10   0    18\n\n\n\n\n\nFigure 6: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 7: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nFigure 8: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\n\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_gent_hinoc <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kpcb_ceftazavi_gent_hinoc.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalhinoc <- fitMarginals(caz_gent_hinoc, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 5.0),\n                            names = c(\"CTZ/AVI\", \"GENT\"))\nsummary(marginalFit2)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              7.937  8.662\nMaximal response  24.000 24.000\nlog10(EC50)        0.588  0.199\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime and gentamicin, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalhinoc) + ggtitle(paste(\"Ceftazidime/Avibactam + Gentamicin\"))\nrshinoc <- fitSurface(caz_gent_hinoc, marginalhinoc,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rshinoc)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 5, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              3.588  4.541\nMaximal response  24.000 24.000\nlog10(EC50)        2.170  1.518\n\nCommon baseline at: 5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n4.988 [3.8144, 6.1365]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n      estimate  lower   upper call\n40_20   7.4256 1.2730 13.5781  Syn\n80_10   7.8653 0.4111 15.3196  Syn\n80_20  12.3250 4.8002 19.8498  Syn\n84_21   9.5696 1.0546 18.0846  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   4   0    12\n\n\nCode\nplot(rshinoc, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 9: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\nCode\n## mean R statistic evaluates how the test evaluates how the predicted response surface based on a specified null model differs from the observed one. If the null hypothesis is rejected, this test suggests that at least some dose combinations may exhibit synergistic or antagonistic behaviour. The meanR test is not designed to pinpoint which combinations produce these effects nor what type of deviating effect is present.\n\n\n\n# maxR test allows to evaluate presence of synergistic/antagonistic effects for each dose combination and as such provides a point-by-point classification.\n\n\nrshhinoc <- fitSurface(caz_gent_hinoc, marginalhinoc,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rshhinoc)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 5, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              3.588  4.541\nMaximal response  24.000 24.000\nlog10(EC50)        2.170  1.518\n\nCommon baseline at: 5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(12,48) = 40.1182 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n      d1 d2      absR p-value call\n40_20 40 20  8.902446  <2e-16  Syn\n40_40 40 40  3.162920 0.03215  Syn\n42_21 42 21  3.424583 0.01508  Syn\n80_10 80 10  4.762522 0.00012  Syn\n80_20 80 20 15.822489  <2e-16  Syn\n80_40 80 40  3.162920 0.03215  Syn\n84_21 84 21  9.277699  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   7   0    12\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n5.3921 [4.9068, 6.2058]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n      estimate  lower   upper call\n40_20   7.5826 3.4242 11.7410  Syn\n80_10   7.9410 2.3937 13.4882  Syn\n80_20  13.9276 9.6843 18.1710  Syn\n84_21  11.4878 6.5496 16.4259  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   4   0    12\n\n\nCode\nrsbhinoc <- fitSurface(caz_gent_hinoc, marginalhinoc, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsbhinoc)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 5, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI   GENT\nSlope              3.588  4.541\nMaximal response  24.000 24.000\nlog10(EC50)        2.170  1.518\n\nCommon baseline at: 5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(12,48) = 24.1709 (p-value = 0)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n      d1 d2      absR p-value call\n40_20 40 20  6.910368  <2e-16  Syn\n40_40 40 40  4.252764 0.00126  Syn\n80_10 80 10  5.240497   1e-05  Syn\n80_20 80 20 11.833922  <2e-16  Syn\n84_21 84 21  5.455699   1e-05  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   5   0    12\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n4.988 [3.6842, 6.6536]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n      estimate  lower   upper call\n40_20   7.4256 1.0353 13.8158  Syn\n80_10   7.8653 0.7390 14.9916  Syn\n80_20  12.3250 5.9078 18.7422  Syn\n84_21   9.5696 2.1216 17.0176  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   4   0    12\n\n\n\n\n\nFigure 10: Effect of combined ceftazidime/avibactam and gentamicin effects on Tpos\n\n\n\n\n\n\n\nResults are shown in ?@fig-12cat.\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_azt <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/ndm_cazavi_azt.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit3cat <- fitMarginals(caz_azt, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"AZT\"))\nsummary(marginalFit3cat)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and aztroenam, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit3cat) + ggtitle(paste(\"Ceftazidime/Avibactam + Aztreonam\"))\nrs3cat <- fitSurface(caz_azt, marginalFit3cat,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs3cat)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n10.3364 [10.3082, 10.3485]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate   lower   upper call\n19.95_1.197    2.0000  1.1506  2.8494  Syn\n19.95_2.394    7.8025  6.9943  8.6107  Syn\n19.95_3.99    14.5000 13.6645 15.3355  Syn\n19.95_4.9875   9.9250  9.0978 10.7521  Syn\n19.95_7.98    14.5000 13.6316 15.3684  Syn\n19.95_9.975   14.5000 13.6415 15.3585  Syn\n39.9_1.197     3.4999  2.6863  4.3134  Syn\n39.9_19.95    12.3749 11.4706 13.2791  Syn\n39.9_2.394     9.8813  9.0761 10.6865  Syn\n39.9_3.99     14.4999 13.6689 15.3308  Syn\n39.9_39.9     14.4999 13.5223 15.4774  Syn\n39.9_4.9875   11.3429 10.5205 12.1653  Syn\n39.9_7.98     14.4999 13.6364 15.3633  Syn\n39.9_79.8     14.4998 13.4583 15.5414  Syn\n39.9_9.975    14.4999 13.6435 15.3563  Syn\n79.8_19.95    14.4971 13.5630 15.4312  Syn\n79.8_39.9     14.4971 13.5204 15.4738  Syn\n79.8_79.8     14.4970 13.4575 15.5365  Syn\n9.975_1.197    2.2200  1.4120  3.0280  Syn\n9.975_2.394    2.3300  1.4954  3.1646  Syn\n9.975_4.9875   2.7000  1.8453  3.5547  Syn\n9.975_9.975    3.8350  2.9557  4.7143  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    22\n\n\nCode\nplot(rs3cat, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 11: Effect of combined ceftazidime/avibactam and aztreonam effects on Tpos\n\n\n\nCode\nrsh3cat <- fitSurface(caz_azt, marginalFit3cat,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh3cat)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(22,32) = 482.777 (p-value < 2e-16)\n\nEvidence for effects in data: Ant\nPoints with significant deviations from the null: \n                 d1      d2      absR p-value call\n19.95_1.197  19.950  1.1970 22.149569  <2e-16  Ant\n19.95_2.394  19.950  2.3940 13.004736  <2e-16  Ant\n19.95_3.99   19.950  3.9900 30.576846  <2e-16  Syn\n19.95_4.9875 19.950  4.9875  4.306253 0.00311  Syn\n19.95_7.98   19.950  7.9800 24.022524  <2e-16  Syn\n19.95_9.975  19.950  9.9750 35.656311  <2e-16  Syn\n39.9_1.197   39.900  1.1970 27.642378  <2e-16  Ant\n39.9_19.95   39.900 19.9500  9.046079  <2e-16  Syn\n39.9_3.99    39.900  3.9900 26.954813  <2e-16  Syn\n39.9_39.9    39.900 39.9000 13.323312  <2e-16  Syn\n39.9_4.9875  39.900  4.9875 11.550743  <2e-16  Syn\n39.9_7.98    39.900  7.9800 21.270610  <2e-16  Syn\n39.9_79.8    39.900 79.8000 10.385527  <2e-16  Syn\n39.9_9.975   39.900  9.9750 27.811309  <2e-16  Syn\n79.8_19.95   79.800 19.9500 11.793525  <2e-16  Syn\n79.8_39.9    79.800 39.9000 10.465298  <2e-16  Syn\n79.8_79.8    79.800 79.8000  7.699994  <2e-16  Syn\n9.975_1.197   9.975  1.1970 35.692823  <2e-16  Ant\n9.975_2.394   9.975  2.3940 29.602031  <2e-16  Ant\n9.975_4.9875  9.975  4.9875 29.154426  <2e-16  Ant\n9.975_9.975   9.975  9.9750 25.180733  <2e-16  Ant\n\nOverall maxR summary:\n Call Syn Ant Total\n  Ant  14   7    22\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n10.3364 [10.3117, 10.3473]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate   lower   upper call\n19.95_1.197    2.0000  1.1029  2.8971  Syn\n19.95_2.394    7.8025  6.9606  8.6443  Syn\n19.95_3.99    14.5000 13.6351 15.3649  Syn\n19.95_4.9875   9.9250  9.0743 10.7757  Syn\n19.95_7.98    14.5000 13.6128 15.3872  Syn\n19.95_9.975   14.5000 13.6314 15.3685  Syn\n39.9_1.197     3.4999  2.6341  4.3656  Syn\n39.9_19.95    12.3749 11.4695 13.2802  Syn\n39.9_2.394     9.8813  9.0329 10.7297  Syn\n39.9_3.99     14.4999 13.6300 15.3697  Syn\n39.9_39.9     14.4999 13.5488 15.4510  Syn\n39.9_4.9875   11.3429 10.4872 12.1986  Syn\n39.9_7.98     14.4999 13.6080 15.3917  Syn\n39.9_79.8     14.4999 13.5241 15.4756  Syn\n39.9_9.975    14.4999 13.6229 15.3768  Syn\n79.8_19.95    14.4971 13.5502 15.4439  Syn\n79.8_39.9     14.4971 13.5404 15.4538  Syn\n79.8_79.8     14.4971 13.5187 15.4755  Syn\n9.975_1.197    2.2200  1.3765  3.0635  Syn\n9.975_2.394    2.3300  1.4643  3.1957  Syn\n9.975_4.9875   2.7000  1.8237  3.5763  Syn\n9.975_9.975    3.8350  2.9482  4.7218  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    22\n\n\nCode\nrsb3cat <- fitSurface(caz_azt, marginalFit3cat,\n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb3cat)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              4.446  5.970\nMaximal response  24.000 24.000\nlog10(EC50)        2.733  2.843\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(22,32) = 508.0207 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n                 d1      d2      absR p-value call\n19.95_1.197  19.950  1.1970 22.458782  <2e-16  Ant\n19.95_2.394  19.950  2.3940 13.484443  <2e-16  Ant\n19.95_3.99   19.950  3.9900 31.413435  <2e-16  Syn\n19.95_4.9875 19.950  4.9875  6.427040  <2e-16  Syn\n19.95_7.98   19.950  7.9800 25.801606  <2e-16  Syn\n19.95_9.975  19.950  9.9750 39.153578  <2e-16  Syn\n39.9_1.197   39.900  1.1970 29.991664  <2e-16  Ant\n39.9_19.95   39.900 19.9500 10.930062  <2e-16  Syn\n39.9_2.394   39.900  2.3940  3.743521 0.01539  Ant\n39.9_3.99    39.900  3.9900 25.716968  <2e-16  Syn\n39.9_39.9    39.900 39.9000 15.759285  <2e-16  Syn\n39.9_4.9875  39.900  4.9875  9.341362  <2e-16  Syn\n39.9_7.98    39.900  7.9800 21.454814  <2e-16  Syn\n39.9_79.8    39.900 79.8000 15.453467  <2e-16  Syn\n39.9_9.975   39.900  9.9750 28.423258  <2e-16  Syn\n79.8_19.95   79.800 19.9500 11.013550  <2e-16  Syn\n79.8_39.9    79.800 39.9000 10.771160  <2e-16  Syn\n79.8_79.8    79.800 79.8000 10.468869  <2e-16  Syn\n9.975_1.197   9.975  1.1970 35.970464  <2e-16  Ant\n9.975_2.394   9.975  2.3940 28.871466  <2e-16  Ant\n9.975_4.9875  9.975  4.9875 27.433089  <2e-16  Ant\n9.975_9.975   9.975  9.9750 22.349685  <2e-16  Ant\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  14   8    22\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n10.3364 [10.3151, 10.3434]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate   lower   upper call\n19.95_1.197    2.0000  1.1659  2.8340  Syn\n19.95_2.394    7.8025  7.0454  8.5596  Syn\n19.95_3.99    14.5000 13.7191 15.2809  Syn\n19.95_4.9875   9.9250  9.1649 10.6850  Syn\n19.95_7.98    14.5000 13.6985 15.3015  Syn\n19.95_9.975   14.5000 13.7252 15.2748  Syn\n39.9_1.197     3.4999  2.7044  4.2953  Syn\n39.9_19.95    12.3749 11.5603 13.1894  Syn\n39.9_2.394     9.8813  9.1150 10.6476  Syn\n39.9_3.99     14.4999 13.7118 15.2879  Syn\n39.9_39.9     14.4999 13.6369 15.3628  Syn\n39.9_4.9875   11.3429 10.5755 12.1102  Syn\n39.9_7.98     14.4999 13.6915 15.3082  Syn\n39.9_79.8     14.4998 13.6331 15.3666  Syn\n39.9_9.975    14.4999 13.7132 15.2865  Syn\n79.8_19.95    14.4971 13.6178 15.3763  Syn\n79.8_39.9     14.4971 13.6140 15.3801  Syn\n79.8_79.8     14.4970 13.6105 15.3835  Syn\n9.975_1.197    2.2200  1.4525  2.9875  Syn\n9.975_2.394    2.3300  1.5417  3.1183  Syn\n9.975_4.9875   2.7000  1.9065  3.4935  Syn\n9.975_9.975    3.8350  3.0366  4.6334  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    22\n\n\n\n\n\nFigure 12: Effect of combined ceftazidime/avibactam and aztreonam effects on Tpos\n\n\n\n\n\n\n\nResults are shown in ?@fig-cat2.\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_mero_cat <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kp_kpc_catania_cazavi_mero.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFitcat2 <- fitMarginals(caz_mero_cat, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"AZT\"))\nsummary(marginalFitcat2)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              9.482  2.472\nMaximal response  24.000 24.000\nlog10(EC50)        2.636  1.651\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and aztroenam, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFitcat2) + ggtitle(paste(\"Ceftazidime/Avibactam + Meropenem\"))\nrs3cat2 <- fitSurface(caz_mero_cat, marginalFitcat2,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs3cat2)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              9.482  2.472\nMaximal response  24.000 24.000\nlog10(EC50)        2.636  1.651\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n2.9104 [0.4981, 4.2813]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n       estimate  lower   upper call\n160_40   8.2526 3.9129 12.5923  Syn\n80_40    5.9200 1.5803 10.2596  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   2   0    11\n\n\nCode\nplot(rs3cat2, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 13: Effect of combined ceftazidime/avibactam and meropenem effects on Tpos\n\n\n\nCode\nrsh3cat2 <- fitSurface(caz_mero_cat, marginalFitcat2,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh3cat2)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              9.482  2.472\nMaximal response  24.000 24.000\nlog10(EC50)        2.636  1.651\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(11,40) = 20.429 (p-value = 0)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n        d1 d2      absR p-value call\n160_20 160 20  5.212307   4e-05  Syn\n160_40 160 40 10.785807  <2e-16  Syn\n80_40   80 40  7.177069  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   3   0    11\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n2.9107 [-0.6493, 5.3431]\nEvidence for effects in data: None \n\nSignificant pointwise effects\n       estimate  lower   upper call\n160_40   8.2533 3.7737 12.7329  Syn\n80_40    5.9200 1.4404 10.3995  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   2   0    11\n\n\nCode\nrsb3cat2 <- fitSurface(caz_mero_cat, marginalFitcat2, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb3cat2)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    AZT\nSlope              9.482  2.472\nMaximal response  24.000 24.000\nlog10(EC50)        2.636  1.651\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(11,40) = 21.4762 (p-value = 0)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n        d1 d2      absR p-value call\n160_20 160 20  5.228880   3e-05  Syn\n160_40 160 40 11.106088  <2e-16  Syn\n80_40   80 40  7.497998  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   3   0    11\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n2.9104 [0.2068, 6.6625]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n       estimate  lower   upper call\n160_40   8.2526 3.8138 12.6914  Syn\n80_40    5.9200 1.4811 10.3588  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   2   0    11\n\n\n\n\n\nFigure 14: Effect of combined ceftazidime/avibactam and meropenem effects on Tpos\n\n\n\n\n\n\n\n\nResults are shown infig13wp2?.\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_col <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kpcb_colistin_cazavi.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit4 <- fitMarginals(caz_col, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"COL\"))\nsummary(marginalFit4)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and colistin, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit4) + ggtitle(paste(\"Ceftazidime/Avibactam + Colistin\"))\nrs4 <- fitSurface(caz_col, marginalFit4,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs4)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.9751 [1.0809, 3.1257]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n             estimate  lower   upper call\n0.95_0.057     3.0903 0.5076  5.6730  Syn\n0.95_0.11875   4.6662 0.1831  9.1493  Syn\n1.9_0.057      5.0066 0.8011  9.2120  Syn\n1.9_0.11875    6.0052 0.1669 11.8434  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   4   0    10\n\n\nCode\nplot(rs4, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 15: Effect of combined ceftazidime/avibactam and colistin effects on Tpos\n\n\n\nCode\nrsh4 <- fitSurface(caz_col, marginalFit4,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh4)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(10,116) = 10.6972 (p-value = 0)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2     absR p-value call\n0.95_0.057   0.95 0.05700 5.135618   1e-05  Syn\n0.95_0.11875 0.95 0.11875 4.185532 0.00049  Syn\n1.9_0.057    1.90 0.05700 4.834160   2e-05  Syn\n1.9_0.11875  1.90 0.11875 6.282205  <2e-16  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   4   0    10\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n2.315 [1.4096, 3.1969]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n            estimate  lower   upper call\n0.95_0.057    3.1029 0.0431  6.1627  Syn\n1.9_0.057     5.1054 0.1468 10.0639  Syn\n1.9_0.11875   9.2794 2.3581 16.2006  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   3   0    10\n\n\nCode\nrsb4 <- fitSurface(caz_col, marginalFit4, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb4)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    COL\nSlope              9.277  5.406\nMaximal response  24.000 24.000\nlog10(EC50)        0.307 -0.879\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(10,116) = 8.9424 (p-value = 0)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n               d1      d2     absR p-value call\n0.95_0.057   0.95 0.05700 4.939011  <2e-16  Syn\n0.95_0.11875 0.95 0.11875 4.706784   3e-05  Syn\n1.9_0.057    1.90 0.05700 5.072593  <2e-16  Syn\n1.9_0.11875  1.90 0.11875 4.099764 0.00076  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   4   0    10\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.9751 [0.9216, 3.4088]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n[1] estimate lower    upper    call    \n<0 rows> (or 0-length row.names)\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   0   0    10\n\n\n\n\n\nFigure 16: Effect of combined ceftazidime/avibactam and colistin effects on Tpos\n\n\n\n\n\n\n\nResults are shown in ?@fig-14wp2.\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_mero <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/caz_avi_meropenem_kpcb.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmfcaz_mero <- fitMarginals(caz_mero, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"MER\"))\nsummary(mfcaz_mero)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    MER\nSlope              9.273 26.309\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.629\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and meropenem, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(mfcaz_mero) + ggtitle(paste(\"Ceftazidime/Avibactam + Meropenem\"))\nrscaz_mero <- fitSurface(caz_mero, mfcaz_mero,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rscaz_mero)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    MER\nSlope              9.273 26.309\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.629\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n11.5398 [11.1794, 11.7478]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n       estimate   lower   upper call\n10_0.4   5.8300  4.5426  7.1174  Syn\n10_1.2   9.2500  7.9626 10.5374  Syn\n10_2.4  12.5000 10.6794 14.3206  Syn\n10_5    13.8300 12.0094 15.6506  Syn\n20_0.3   4.0000  2.1794  5.8206  Syn\n20_0.4  14.5000 13.2126 15.7873  Syn\n20_1.2  14.5000 13.2126 15.7873  Syn\n20_10   14.5000 12.6794 16.3206  Syn\n20_2.4  14.5000 12.6794 16.3206  Syn\n20_20   14.5000 12.6794 16.3206  Syn\n20_40   12.1159 10.2325 13.9994  Syn\n20_5    14.0000 12.7126 15.2873  Syn\n40_0.3  14.4869 12.6662 16.3077  Syn\n40_0.4  14.4869 12.6662 16.3077  Syn\n40_10   14.4869 12.6662 16.3077  Syn\n40_20   14.4869 12.6662 16.3077  Syn\n40_40   12.1050 10.2225 13.9875  Syn\n40_5    14.4869 12.6662 16.3077  Syn\n80_10    9.3049  7.4498 11.1601  Syn\n80_20    9.3049  7.4498 11.1601  Syn\n80_40    7.7750  5.9141  9.6359  Syn\n80_5     9.3049  7.4498 11.1601  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    23\n\n\nCode\nplot(rscaz_mero, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 17: Effect of combined ceftazidime/avibactam and tigecycline effects on Tpos\n\n\n\nCode\nrshcaz_mero <- fitSurface(caz_mero, mfcaz_mero,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rshcaz_mero)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    MER\nSlope              9.273 26.309\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.629\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(23,125) = 45.3163 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n       d1   d2      absR p-value call\n10_0.4 10  0.4  4.196115 0.00105  Syn\n10_1.2 10  1.2  6.657646  <2e-16  Syn\n10_2.4 10  2.4  6.361714  <2e-16  Syn\n10_5   10  5.0  7.038601  <2e-16  Syn\n20_0.4 20  0.4 10.435897  <2e-16  Syn\n20_1.2 20  1.2 10.435897  <2e-16  Syn\n20_10  20 10.0  7.379333  <2e-16  Syn\n20_2.4 20  2.4  7.379333  <2e-16  Syn\n20_20  20 20.0  7.379333  <2e-16  Syn\n20_40  20 40.0  5.778604   1e-05  Syn\n20_5   20  5.0 10.076024  <2e-16  Syn\n40_0.3 40  0.3  7.350492  <2e-16  Syn\n40_0.4 40  0.4  7.350492  <2e-16  Syn\n40_10  40 10.0  7.350492  <2e-16  Syn\n40_20  40 20.0  7.350492  <2e-16  Syn\n40_40  40 40.0  5.778604   1e-05  Syn\n40_5   40  5.0  7.350492  <2e-16  Syn\n80_10  80 10.0  4.068120 0.00181  Syn\n80_20  80 20.0  4.068120 0.00181  Syn\n80_40  80 40.0  4.068120 0.00181  Syn\n80_5   80  5.0  4.068120 0.00181  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  21   0    23\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n11.6068 [11.0523, 11.9538]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n       estimate   lower   upper call\n10_0.4   5.8300  4.5573  7.1027  Syn\n10_1.2   9.2500  7.9773 10.5227  Syn\n10_2.4  12.5000 10.7002 14.2998  Syn\n10_5    13.8300 12.0302 15.6298  Syn\n20_0.3   4.0000  2.2001  5.7998  Syn\n20_0.4  14.5000 13.2273 15.7727  Syn\n20_1.2  14.5000 13.2273 15.7727  Syn\n20_10   14.5000 12.7001 16.2998  Syn\n20_2.4  14.5000 12.7001 16.2998  Syn\n20_20   14.5000 12.7001 16.2998  Syn\n20_40   12.1159 10.2644 13.9675  Syn\n20_5    14.0000 12.7273 15.2727  Syn\n40_0.3  14.4869 12.6868 16.2870  Syn\n40_0.4  14.4869 12.6868 16.2870  Syn\n40_10   14.4869 12.6868 16.2870  Syn\n40_20   14.4869 12.6868 16.2870  Syn\n40_40   12.1159 10.2644 13.9675  Syn\n40_5    14.4869 12.6868 16.2870  Syn\n80_10    9.3049  7.4374 11.1725  Syn\n80_20    9.3049  7.4374 11.1725  Syn\n80_40    9.3049  7.4374 11.1725  Syn\n80_5     9.3049  7.4374 11.1725  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    23\n\n\nCode\nrsb_caz_mero <- fitSurface(caz_mero, mfcaz_mero, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb_caz_mero)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    MER\nSlope              9.273 26.309\nMaximal response  24.000 24.000\nlog10(EC50)        1.930  1.629\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(23,125) = 45.3688 (p-value < 2e-16)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n       d1   d2      absR p-value call\n10_0.4 10  0.4  4.196120 0.00109  Syn\n10_1.2 10  1.2  6.657651  <2e-16  Syn\n10_2.4 10  2.4  6.361717  <2e-16  Syn\n10_5   10  5.0  7.038604  <2e-16  Syn\n20_0.4 20  0.4 10.436234  <2e-16  Syn\n20_1.2 20  1.2 10.436234  <2e-16  Syn\n20_10  20 10.0  7.379539  <2e-16  Syn\n20_2.4 20  2.4  7.379539  <2e-16  Syn\n20_20  20 20.0  7.379538  <2e-16  Syn\n20_40  20 40.0  5.746443  <2e-16  Syn\n20_5   20  5.0 10.076361  <2e-16  Syn\n40_0.3 40  0.3  7.364468  <2e-16  Syn\n40_0.4 40  0.4  7.364468  <2e-16  Syn\n40_10  40 10.0  7.364468  <2e-16  Syn\n40_20  40 20.0  7.364467  <2e-16  Syn\n40_40  40 40.0  5.734395  <2e-16  Syn\n40_5   40  5.0  7.364468  <2e-16  Syn\n80_10  80 10.0  4.321396 0.00063  Syn\n80_20  80 20.0  4.321396 0.00063  Syn\n80_40  80 40.0  3.347345 0.02431  Syn\n80_5   80  5.0  4.321396 0.00063  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn  21   0    23\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n11.5398 [10.9505, 11.88]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n       estimate   lower   upper call\n10_0.4   5.8300  4.4960  7.1640  Syn\n10_1.2   9.2500  7.9160 10.5840  Syn\n10_2.4  12.5000 10.6134 14.3866  Syn\n10_5    13.8300 11.9434 15.7166  Syn\n20_0.3   4.0000  2.1134  5.8866  Syn\n20_0.4  14.5000 13.1660 15.8340  Syn\n20_1.2  14.5000 13.1660 15.8340  Syn\n20_10   14.5000 12.6134 16.3866  Syn\n20_2.4  14.5000 12.6134 16.3866  Syn\n20_20   14.5000 12.6134 16.3866  Syn\n20_40   12.1159 10.1648 14.0670  Syn\n20_5    14.0000 12.6660 15.3340  Syn\n40_0.3  14.4869 12.6003 16.3736  Syn\n40_0.4  14.4869 12.6003 16.3736  Syn\n40_10   14.4869 12.6003 16.3736  Syn\n40_20   14.4869 12.6003 16.3736  Syn\n40_40   12.1050 10.1538 14.0562  Syn\n40_5    14.4869 12.6003 16.3736  Syn\n80_10    9.3049  7.3647 11.2452  Syn\n80_20    9.3049  7.3647 11.2452  Syn\n80_40    7.7750  5.8306  9.7195  Syn\n80_5     9.3049  7.3647 11.2452  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n  22   0    23\n\n\n\n\n\nFigure 18: Effect of combined ceftazidime/avibactam and tigecycline effects on Tpos\n\n\n\n\n\n\n\nResults are shown in ?@fig-15wp2\n\n\nCode\nlibrary(BIGL)\nlibrary(knitr)\nlibrary(rgl)\nlibrary(ggplot2)\nlibrary(broom)\nlibrary(kableExtra)\nset.seed(12345)\ncutoff <- 0.95\ncaz_tig <- read.csv(\"~/Desktop/ACUTEWEBSITE/datasets_combo/kcb_cazavi_tig.csv\")\n## Fitting marginal models, maximal fixed at 24 hours, minimal at 9.5 hours\nmarginalFit6 <- fitMarginals(caz_tig, method = \"optim\",                 \n                            fixed = c(\"m1\" = 24, \"m2\" = 24, \"b\" = 9.5),\n                            names = c(\"CTZ/AVI\", \"TIG\"))\nsummary(marginalFit6)\n\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\n\nCode\n## Plotting marginal model for ceftazidime/avibactam and tigecycline, minimum constrained at 9 hrs and maximum constrained at 24 hours\nplot(marginalFit6) + ggtitle(paste(\"Ceftazidime/Avibactam + Tigecycline\"))\nrs6 <- fitSurface(caz_tig, marginalFit6,\n                 null_model = \"bliss\",\n                 B.CP = 50, statistic = \"none\", parallel = FALSE)\nsummary(rs6)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\n\n\nNo test statistics were computed.\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.6626 [0.7233, 2.7338]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower  upper call\n79.8_19.95   1.6400 0.4535 2.8265  Syn\n79.8_9.975   2.3744 1.2413 3.5075  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   2   0     3\n\n\nCode\nplot(rs6, legend = FALSE, main = \"\")\nview3d(0, -75)\nrglwidget()\n\n\n\n\n\nFigure 19: Effect of combined ceftazidime/avibactam and tigecycline effects on Tpos\n\n\n\nCode\nrsh6 <- fitSurface(caz_tig, marginalFit6,\n                  null_model = \"hsa\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsh6)\n\n\nNull model: Highest Single Agent with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(3,75) = 4.8073 (p-value = 0.0041)\n\nEvidence for effects in data: Syn\nPoints with significant deviations from the null: \n             d1    d2    absR p-value call\n79.8_19.95 79.8 19.95 2.75595 0.02189  Syn\n\nOverall maxR summary:\n Call Syn Ant Total\n  Syn   1   0     3\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n2.704 [1.6392, 3.6561]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower  upper call\n79.8_19.95   3.5137 2.1299 4.8976  Syn\n79.8_39.9    2.0597 0.6517 3.4676  Syn\n79.8_9.975   2.5387 1.1549 3.9226  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   3   0     3\n\n\nCode\nrsb6 <- fitSurface(caz_tig, marginalFit6, \n                  null_model = \"bliss\",\n                  B.CP = 50, statistic = \"both\", parallel = FALSE)\nsummary(rsb6)\n\n\nNull model: Bliss independence with shared maximal response\nVariance assumption used: \"equal\"\n\nFormula: effect ~ fn(h1, h2, b = 19/2, m1 = 24, m2 = 24, e1, e2, d1, d2)\nTransformations: No\n\n                 CTZ/AVI    TIG\nSlope             10.087  3.789\nMaximal response  24.000 24.000\nlog10(EC50)        1.935  1.467\n\nCommon baseline at: 9.5\n\nExact meanR test (H0 = no synergy/antagonism):\n    F(3,75) = 1.8988 (p-value = 0.1371)\nMaxR test did not detect any deviations from the null.\n\nCONFIDENCE INTERVALS\nOverall effect\nEstimated mean departure from null response surface with 95% confidence interval:\n1.6626 [0.6256, 2.5476]\nEvidence for effects in data: Syn \n\nSignificant pointwise effects\n           estimate  lower  upper call\n79.8_19.95   1.6400 0.3335 2.9466  Syn\n79.8_9.975   2.3744 1.1403 3.6085  Syn\n\nPointwise 95% confidence intervals summary:\n Syn Ant Total\n   2   0     3\n\n\n\n\n\nFigure 20: Effect of combined ceftazidime/avibactam and tigecycline effects on Tpos"
  },
  {
    "objectID": "Presentations.html",
    "href": "Presentations.html",
    "title": "Presentations",
    "section": "",
    "text": "Coming soon!"
  },
  {
    "objectID": "Timeline.html",
    "href": "Timeline.html",
    "title": "Timeline",
    "section": "",
    "text": "Coming soon!"
  },
  {
    "objectID": "Protocols.html",
    "href": "Protocols.html",
    "title": "Protocols",
    "section": "",
    "text": "sterile 15 ml falcon tube \nglass tubes\ntube racks\nDensiCHEK plus Biomerieux\nVortex\n100-1000 mcl mechanical pipette\n1 ml sterile insulin syringe\nserum from healthy volunteers\nsaline sterile solution\nMH broth\nBacT/ALERT FA FAN® Aerobic Biomeriuex blood culture bottles\nBacT/ALERT SA Standard Aerobic Biomerieux blood culture bottles (without inactivating matrix)\nBact/ALERT 3D Biomerieux incubator system\n\n\n\n\n\nBacterial strains were obtained from the banked collection of the Microbiology Unit, Hub Laboratory, AUSL Romagna, Cesena, Italy.\nEach day before testing, strains are thawed and incubated at 37°C for 18-24 hours.\nMICs were confirmed by Etest using the manufacturer’s recommendations\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nIsolate\nAbbreviation\nEnzyme\nSource\nCeftazidime/Avibactam MIC (mg/L)\nCeftazidime\nGentamicin\nMeropenem\nTigecycline\nMeropenem-Vaborbactam\nColistin\nCiprofloxacin\nAmpicillin\n\n\n\n\nKlebsiella pneumonia\nKI_WT\nWild type\nclinical isolate\n0.125\n0.125\n\n\n1\n\n\n<=0.06\n\n\n\nKlebsiella pneumoniae ESBL ATCC 700603\nKP_ATCC\nbla SHV-18\nReference strain\n0.75\n12\n\n0.03\n4\n\n\n\n\n\n\nKlebsiella pneumoniae KPC- A\nKPC_A\nKPC-3\nClinical isolate\n2\n\n2\n\n0.75\n\n0.38\n\n\n\n\nKlebsiella pneumoniae KPC- B\nKPC_B\nKPC-3\nClinical isolate\n1\n\n0.5\n32\n0.38\n\n\n\n\n\n\nKlebsiella pneumoniae KPC- C\nKPC_C\nKPC-3\nClinical isolate\n\n\n\n>256\n\n\n\n\n\n\n\nKlebsiella penumonia Catannia\nKPC-Catania\n\nClinical isolate\n16\n\n\n\n\n\n\n\n\n\n\nKlebsiella pneumoniae NDM\nKP_NDM\nNDM-2\nClinical isolate\n>256\n\n\n>256\n\n\n\n\n\n\n\nKlebsiella pneumonia VIM\nKP_VIM\nVIM\nClinical isolate\n>256\n\n\n>256\n\n\n\n\n\n\n\nEscherichia coli ATCC 25922\nEC_ATCC\n\nATCC\n\n0.19\n\n\n0.125\n\n\n0.012\n4\n\n\nKlebsiella pneumonia\nKP_Dam\n\nClinical isolate\n\n4\n\n\n\n\n\n\n\n\n\nKlebsiella pneumonia\nKP_FAB\nESBL\n\n\n\n\n\n\n\n\n\n\n\n\nKlebsiella pneumonia\nKP_Cav\n\n\n\n16\n\n\n\n\n\n4\n\n\n\nEscherichia coli\nEC_Mont\n\n\n\n64\n\n\n\n\n\n>32\n4\n\n\nEscherichia coli\nEC_Rossi\n\n\n\n8\n\n\n\n\n\n>32\n\n\n\nPseudomonas aeruginosa ATCC 27853\nPA_ATCC\n\n\n\n1\n\n0.38\n\n\n\n0.125\n\n\n\nPseudononas aeruginosa\nPA_Fabri\n\n\n\n\n\n>32\n\n\n\n\n\n\n\n\nMICs were performed and confirmed by Etest\n\n\n\nThe proposed method are a modification of Tpos assay as proposed by Kaltsas et al.\nDilution schemes are from the Clinical Laboratory Standards Institute (CLSI) M21-A Methodology for the Serum Bactericidal Test and M26A Methodology for Determining Bactericidal Activity of Antibiotics.\nTo prepare a standardized inoculum (1.5 x102 CFU/mL) for injection in blood culture bottles:\n\nColonies are selected from an 18- to 24-hour agar plate and suspended in sterile 0.9% phosphate buffered saline (PBS) in a glass test tube. The suspension is then adjusted by optimal density using a Densichek turbidity meter to an equivalent to a 0.5 McFarland standard corresponding to 1 to 2 × 108 CFU/mL.\nThe inoculum is then serially diluted using ten-fold dilution scheme: 200 μL inoculum dispensed by micropipette into 1800 μL 0.9% saline → vortexed → then 200 μL of this suspension is pipetted into a fresh tube containing 1800 μL 0.9% saline, etc.) until a final inoculum of 1.5 x102 CFU/ml is reached.\n\nNote the final dilution step is repeated an additional 5 times in replicate tubes to ensure 6 tubes (12 mL of the final 1.5 x102 CFU/mL) are available to inoculate 10 blood culture bottles.\n\n\n\n\n\nAnalytical grade (> 99% pure) ceftazidime (200 μg/mL) and avibactam (500 μg/mL) pure powder are diluted separately in sterile water to prepare a stock solution of ceftazidime (200 μg/mL) and avibactam (500 μg/mL). The stock solution is dispensed into 2 mL sterile cryo-vials and stored at -20°C.\nFrozen stock antibiotic solution in cryo-vials is thawed the day of the experiment and diluted at twice the final test concentration using either (a) pooled patient serum; or (b) 0.9% PBS.\n\nExample: to obtain 2 mL of 20 mcg/ml stock: 200 μL of ceftazidime 200 mg/mL solution is pipetted into a test-tube containing 1800 μL of serum\nExample to obtain 50 μg/mL: using the multipipettor set at 500 μL, 500 μL of ceftazidime 200 μg/ml solution are added in a tube containing 1500 μL of serum\n500 μL of the ceftazidime 2x concentration and 500 μL of the 2x avibactam concentration are then added in a test tube to obtain 1 ml of serum-antibiotic solution at the desired concentrations\n\nAfter vortexing for 7-10 seconds each tube, 1 ml of inoculum suspension at 1.5x102 CFU/mL and 1 mL of antibiotic containing serum are inoculated with a sterile insulin syringe into a blood culture bottle containing 40 mL of enrichment broth without inactivating matrix.\nBloodculture bottles are then incubated into Bact/ALERT system to detect growth. The same procedure is repeated for all the selected antibiotic concentration-inoculum pairs.\nOne bottle is inoculated with the bacterial inoculum without adding the antibiotic solution (drug-free control).\n\n\n\n\nTo obtain a series of ten-fold diluted inoculum to be inoculated in each blood culture bottle.\n\nBase inoculum: Colonies are selected from an 18- to 24-hour agar plate and suspended in saline solution 0.9% in a glass test tube. The suspension is adjusted by optimal density by the Densichek plus instrument to achieve turbidity equivalent to a 1 McFarland standard that corresponds to 3 × 108 CFU/mL.\nThe inoculum is then serially ten-fold diluted in 0.9% saline to obtain subsequent inocula down to 3 x101 CFU/ml.\nUsing a multipipettor, 200 μL are withdrawn from tube 1 (inoculum 3 x108 CFU/mL) and added to tube 2 which contains 1800 μL of saline solution (3x107 CFU/mL). The same procedure is repeated serially to produce an inoculum dilution series down to 3 x101 CFU/mL. With each pipette transfer, the suspension is mixed up and down 6-8 times before the subsequent transfer of 200 μL.\n1 ml of each dilution is inoculated with a sterile 1 ml syringe into a blood culture bottle for aerobic incubation (BacT/ALERT FA FAN® Aerobic Biomeriuex)\nBlood culture bottles are incubated into the Bact/ALERT 3D Biomerieux incubator system for 24 hours that automatically reports time to positivity; \nThe day after, time to positivity (defined as the time from the start of incubation to detection of growth) is reported for every bottle.\n\n\n\n\nInoculum preparation: to obtain 1ml of inoculum of 1.5 x104 CFU/mL to be inoculated in each blood culture bottle. The procedure is partly similar to methodology for Workpackage 1A.\n\n\nBase inoculum: Colonies are selected from an 18- to 24-hour agar plate and suspended in saline solution 0.9% in a glass test tube. The suspension is adjusted by optimal density by the Densichek plus instrument to achieve turbidity equivalent to a 0.5 McFarland standard that corresponds to 1 to 2 × 108 CFU/mL.\nThe inoculum is then serially ten-fold diluted 0.9% saline to obtain a final inoculum of 1.5 x104 CFU/ml.\nUsing a multipipettor, 300 μL are withdrawn from tube 1 (inoculum 1.5 x108 CFU/mL) and added to tube 2 which contains 2700 μL of saline solution (1.5x107 CFU/mL). The same procedure is repeated serially to produce an inoculum dilution series down to 1.5 x105 CFU/mL. With each pipette transfer, the suspension is mixed up and down 6-8 times before the subsequent transfer or 300 μL. Last dilution is performed by withdrawing 300 μL from tube 4 and adding this to tube 5 which contains 2700 μL of MH broth; since the glass tubes contain a maximum of 3-4 mL, this last step is repeated for at least 4 tubes in parallel to obtain a total amount of 12 mL of inoculum 1.5 x104 CFU/ml (approximately 10 antibiotic dilutions and 10 blood culture bottles that are inoculated with 1 mL of bacterial inoculum).\n\n\n\n\n\n\n\nNote\n\n\n\nAlternative procedure: last dilution is performed by withdrawing 1 mL from tube 4 and adding this to a 15 mL sterile falcon tube that contains 9 mL of MH broth; this last step is repeated twice and it permits to obtain a total amount of 20 mL of inoculum 1.5 x104 CFU/ml.\n\n\n\n\n\n\n\n\nceftazidime and avibactam pure powder are diluted in sterile water and conserved at -20°C \n\n\nStocked 200 mcg/ml of ceftazidime solution and 500 mcg/ml of avibactam solution are thawed at room temperature\nFurther dilution to obtain the desired concentrations: antimicrobial solutions are calculated at twice the desired final concentration\n\n\n\n\n\n\n\nNote\n\n\n\nFor example: from ceftazidime 200 μg/mL, how to obtain 2 mL of 20 μg/mL stock: using the multipipettor set at 200 mcl, 200 mcl of ceftazidime 200 mcg/mL solution are added in a tube containing 1800 μL of serum.\nFor example: from ceftazidime 200 μg/ml, how to obtain 50 mcg/ml: using the multipipettor set at 500 μL, 500 μL of ceftazidime 200 μg/mL solution are added in a tube containing 1500 μL of serum.\n\n\n\n500 μL of the doubled desired ceftazidime concentration and 500 μL of the doubled desired avibactam concentration are added in a test tube to obtain 1 ml of serum-antibiotic solution at the desired concentrations\n\n\n\n\n\n\n\nNote\n\n\n\nAlternative procedure: ceftazidime and avibactam pure powders are diluted in sterile water and conserved at -20°C\n\n\n\nStocked ceftazidime and avibactam solutions are thawed at room temperature\nConsidering the blood culture bottles containing 40 mL of enrichment broth, antibiotic stocked solutions are further diluted to obtain concentrations 40 times the MIC values or its multiples.\n\n\n\n\n\n\n\nNote\n\n\n\nExample: ceftazidime pure powder is diluted to obtain a concentration of 320 μg/mL in 1 mL of serum that corresponds to a final concentration of 8 μg/ml after inoculation into the blood culture bottle.\n\n\n\nAntimicrobial solutions are calculated at twice the desired final concentration; 500 μL of the doubled desired ceftazidime concentration and 500 μL of the doubled desired avibactam concentration are added in a test tube to obtain 1 mL of serum-antibiotic solution at the desired concentrations\n\n\n\n\n\n\n\nNote\n\n\n\nExample: to test a final concentration of ceftazidime 2 μg/mL and avibactam 0.5 μg/mL, ceftazidime and avibactam are respectively diluted to obtain a concentration of 160 μg/mL and 40 μg/mL. 500 μL of each antibiotic are added in a test tube to obtain a concentration of 80-20 μg/mL which correspond to a final concentration inside the blood culture bottle of 2-0.5 μg/mL.\n\n\n\nAfter vortexing for 7-10 seconds each tube, 1 ml of inoculum suspension at 1.5x104 CFU/ml and 1 ml of serum with antibiotic concentration are inoculated with a sterile 1 ml insulin syringe into a blood culture bottle containing 40 ml of enrichment broth without inactivating matrix (BacT/ALERT SA Standard Aerobic Biomerieux) and incubated into the Bact/ALERT 3D Biomerieux incubator system for 24 hours that automatically detects growth.\nThe same procedure is repeated for all the selected antibiotic concentration-inoculum pairs; one bottle is inoculated with the bacterial inoculum adding 1 mL of saline solution without antibiotic as control.\nThe day after, time to positivity (defined as the time from the start of incubation to detection of growth) is reported for every bottle; bottles showing no growth at 24 hours are reported as “24”."
  }
]